UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 1 of 68 PROTOCOL EP0065 AMEN DMENT 1  
A MULTICENTER, OPEN -LABEL STUDY TO EVALU ATE THE 
PHARMACOKINETICS, SA FETY, AND TOLERABILI TY OF 
INTRAVENOUS BRIVARAC ETAM IN SUBJECTS ≥1 MONTH 
TO <16 YEARS OF AGE WITH EPILEPSY  
PHASE 2  
 
EudraCT Number: 2016 -002452 -25 
IND Number: 103908  
 
 
UCB BIOPHARMA SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
 
Protocol/Amendment number  Date  Type of 
amendment  
Final Protocol  17 Mar 2017  Not applicable  
Protocol Amendment 1  19 Jun 2019  Nonsubstantial  
Confidential Material  
Confidential  
This document is the property of  UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 2 of 68 STUDY CONTACT INFORMATION  
Sponsor  
UCB BIOPHARMA SPRL  
Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Sponsor Study Physicia n 
Name:   , MD , PhD  
Address:  Alfred -Nobel -Strasse 10  
40789 Monheim  
GERMANY  
Phone:   
 
Fax:  
Clinical Project Manager  
Name:  , PhD  
Address:  Alfred -Nobel -Strasse 10  
40789 Monheim  
GERMANY  
Phone:   
Fax:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 3 of 68 Clinical Trial Biostatistician  
Name:  , MS c 
Address:  UCB Celltech  
Bath Road, 208  
Berkshire  
Slough SL1 3WE  
UK 
Phone:   
Clinical Monitoring Contract Research Organization  
Name:  PRA Health Sciences  
Address:  4130 Park Lake Avenue, Suite 400  
Raleigh, NC 27612  
UNITED STATES  
Phone:  +1 919 786 8200  
Fax: +1 919 786 8201  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 4 of 68 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: +32 2 386 24 21  
US and Canada:  +1 800 880 6949 or +1 866 890 3175  
Email  Global:  DS_ICT@ucb.com  
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 5 of 68 TABLE OF CONTENTS  
LIST OF ABBREVIATION S ................................ ................................ ................................ .. 10 
1 SUMMARY  ................................ ................................ ................................ .....................  12 
2 INTRODUCTION  ................................ ................................ ................................ ...........  14 
3 STUDY OBJECTIVES  ................................ ................................ ................................ .... 15 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 16 
4.1 Pharmacokinetic variables  ................................ ................................ ...............................  16 
4.2 Safety variables  ................................ ................................ ................................ ................  16 
4.2.1  Primary safety variables  ................................ ................................ ......................  16 
4.2.2 Other safety variables  ................................ ................................ ..........................  16 
5 STUDY DESIGN  ................................ ................................ ................................ .............  16 
5.1 Study description  ................................ ................................ ................................ .............  16 
5.1.1  Study duration per subject and definition for start/end of study ..........................  19 
5.1.2  Planned number of subjects and sites  ................................ ................................ .. 19 
5.1.3  Anticipated regions and countries  ................................ ................................ ....... 19 
5.2 Schedule of study assessments  ................................ ................................ .........................  19 
5.3 Rationale for study design and selection of dose  ................................ .............................  26 
6 SELECTION AND WITHDR AWAL OF SUBJECTS  ................................ ...................  27 
6.1 Inclusion criteria  ................................ ................................ ................................ ..............  27 
6.2 Exclusion criteria  ................................ ................................ ................................ .............  28 
6.3 Withdrawal criteria  ................................ ................................ ................................ ..........  29 
6.3.1  Potential drug -induced liver injury investigational medicinal product 
discontinuation criteria  ................................ ................................ ........................  30 
7 STUDY TREATMENT(S)  ................................ ................................ ..............................  31 
7.1 Description of investigational medicinal products  ................................ ..........................  31 
7.1.1  Film -coated tablets for oral administration  ................................ ..........................  31 
7.1.2  Oral solution  ................................ ................................ ................................ ........  31 
7.1.3  Solution for iv injection  ................................ ................................ .......................  31 
7.2 Treatments to be administered  ................................ ................................ .........................  31 
7.2.1  Screening, IOB Treatment, and iv PK Periods  ................................ ....................  32 
7.2.2  Down -Titration Period  ................................ ................................ .........................  33 
7.3 Packaging  ................................ ................................ ................................ .........................  33 
7.4 Labeling  ................................ ................................ ................................ ...........................  33 
7.5 Handling and storage requirements ................................ ................................ ..................  34 
7.6 Drug accountability  ................................ ................................ ................................ ..........  34 
7.7 Procedures for monitoring subject compliance  ................................ ................................  34 
7.8 Concomitant medication(s)/treatment(s) ................................ ................................ ..........  35 
7.8.1  Permitted concomitant treatments (medications and therapies)  ..........................  35 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 6 of 68 7.8.2  Prohibited concomitant treatments (medications and therapies)  .........................  35 
7.8.3  Rescue medication  ................................ ................................ ...............................  35 
7.9 Blinding  ................................ ................................ ................................ ............................  35 
7.10  Randomization and numbering of subjects  ................................ ................................ ...... 35 
8 STUDY PROCEDURES BY VISIT  ................................ ................................ ...............  36 
8.1 Visit 1 (Day -10 to Day -1 for OLB, RxB, and IIB subjects; Day  -20 to Day  -11 for IOB 
subjects)  ................................ ................................ ................................ ...........................  36 
8.2 Visit 2 (Day -10 to Day -1; IOB subjects only)  ................................ ...............................  36 
8.3 Visit 3 (Day 1) through Visit 12 (Day 6)  ................................ ................................ .........  37 
8.4 TC-1 (Day 2 to Day 9) (all subjects who received iv BRV)  ................................ ............  38 
8.5 TC-2 38 
8.6 Visit 13  ................................ ................................ ................................ .............................  38 
8.7 TC-3 39 
8.8 Unscheduled Visit  ................................ ................................ ................................ ............  39 
9 ASSESSMENT OF PHARMA COKINETIC VARIABLES  ................................ ...........  39 
10 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  40 
10.1  Adver se events  ................................ ................................ ................................ .................  40 
10.1.1  Definitions  ................................ ................................ ................................ ...........  40 
10.1.1.1  Adverse event  ................................ ................................ ............................  40 
10.1.1.2  Serious adverse event  ................................ ................................ ................  40 
10.1.1.3  Adverse events of special interest  ................................ .............................  41 
10.1.2  Procedures for reporting and recording adverse events  ................................ ....... 42 
10.1.2.1  Description of adverse events  ................................ ................................ .... 42 
10.1.2.2  Rule for repetition of an adverse event ................................ ......................  42 
10.1.2.3  Additional procedures for reporting serious adverse events  .....................  42 
10.1.3  Follow up of adverse events  ................................ ................................ ................  43 
10.1.4  Pregnancy  ................................ ................................ ................................ ............  44 
10.1.5  Suspected transmission of an infectious agent via a medicinal product  ..............  45 
10.1.6  Overdose of investigational medicinal product  ................................ ...................  45 
10.1.7  Safety signal detection  ................................ ................................ .........................  45 
10.2 Laboratory measurements  ................................ ................................ ................................  45 
10.2.1  Evaluation of PDILI  ................................ ................................ ............................  46 
10.2.1.1  Consultation with Medical Monitor and local hepatologist  ......................  51 
10.2.1.2  Immediate action: determination of IMP discontinuation  .........................  51 
10.2.1.3  Testing: identification/exclusion of alternative etiology  ...........................  51 
10.2.1.4  Follow -up evaluation  ................................ ................................ .................  53 
10.3  Other safety measurements  ................................ ................................ ..............................  53 
10.3.1  ECG  ................................ ................................ ................................ .....................  53 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 7 of 68 10.3.2  Vital signs  ................................ ................................ ................................ ............  54 
10.3.3  Assessment of suicidality  ................................ ................................ ....................  55 
11 STUDY MANAGEMENT AND  ADMINISTRATION  ................................ .................  56 
11.1  Adherence to protocol  ................................ ................................ ................................ ...... 56 
11.2  Monitoring  ................................ ................................ ................................ .......................  56 
11.2.1  Definition of source data  ................................ ................................ .....................  57 
11.2.2  Source data verification  ................................ ................................ .......................  57 
11.3  Data handling  ................................ ................................ ................................ ...................  57 
11.3.1  Case Report form completion  ................................ ................................ ..............  57 
11.3.2  Database entry and reconciliation  ................................ ................................ ........  58 
11.3.3  Subject Screening and Enrollment log/Subject Identification Code list ..............  58 
11.4  Termination of the study  ................................ ................................ ................................ .. 58 
11.5  Archiving and data retention  ................................ ................................ ............................  58 
11.6  Audit and inspection  ................................ ................................ ................................ ........  59 
11.7  Good Clinical Practice  ................................ ................................ ................................ ..... 59 
12 STATISTICS  ................................ ................................ ................................ ...................  59 
12.1  Definition of analysis sets  ................................ ................................ ................................  59 
12.2  General statistical considerations  ................................ ................................ .....................  59 
12.3  Planned PK analyses  ................................ ................................ ................................ ........  60 
12.4  Planned safety analyses  ................................ ................................ ................................ .... 60 
12.4.1 Analysis of safety variables  ................................ ................................ .................  60 
12.4.1.1  Primary safety variables  ................................ ................................ ............  60 
12.4.1.2  Other safety variables  ................................ ................................ ................  60 
12.5  Handling of protocol deviations  ................................ ................................ .......................  60 
12.6  Handling of dropouts or missing data  ................................ ................................ ..............  61 
12.7  Planned interim analysis and data monitoring  ................................ ................................ . 61 
12.8  Determination of sample size  ................................ ................................ ...........................  61 
13 ETHICS AND REGULATOR Y REQUIREMENTS  ................................ ......................  61 
13.1  Informed consent  ................................ ................................ ................................ .............  61 
13.2  Subject identification cards  ................................ ................................ ..............................  62 
13.3  Institutional Review Boards and Independent Ethics Committees  ................................ .. 62 
13.4  Subject privacy  ................................ ................................ ................................ .................  63 
13.5  Protocol amendments  ................................ ................................ ................................ ....... 63 
14 FINANCE, INSURANCE, AND PUBLICATION  ................................ .........................  63 
15 REFERENCES  ................................ ................................ ................................ ................  64 
16 APPENDIX  ................................ ................................ ................................ ......................  65 
16.1  Protocol Amendmen t 1 ................................ ................................ ................................ .... 65 
17 DECLARATION AND SIGN ATURE OF INVESTIGATO R ................................ ....... 67 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 8 of 68 18 SPONSOR DECLARATION  ................................ ................................ ..........................  68 
 
 
LIST OF TABLES  
Table  5‒1:  Schedule of Study Assessments (Screening Period through end of iv  PK 
Period)  ................................ ................................ ................................ ..............  20 
Table  5‒2:  Schedule for iv  PK Period ECGs, vital signs, and PK sampling (15 -min 
BRV infusion)  ................................ ................................ ................................ .. 23 
Table  5‒3:  Schedule for iv  PK Period ECGs, vit al signs, and PK sampling (bolus [up 
to 2-min BRV infusion])  ................................ ................................ ..................  24 
Table  5‒4:  Schedule of study assessments for Down -Titration and Safe ty (BRV -free) 
Periods (subjects not continuing into the Long ‑Term, Open ‑Label Study)  ... 25 
Table  7‒1:  BRV dosing during the Screening, IOB Treatment, and iv  PK Periods  ..........  32 
Table  10‒1:  Anticipated serious adverse events for the pediatric epilepsy population  ....... 41 
Table  10‒2:  Laboratory parameters  ................................ ................................ .....................  46 
Table  10‒3:  Required investigations and follow up for PDILI ................................ ............  48 
Table  10‒4:  PDILI laboratory measurements  ................................ ................................ ...... 52 
Table  10‒5:  PDILI information to be collected  ................................ ................................ ... 53 
Table  10-6: PCS Abnormality criteria for the measurement of blood pressure  ..................  55 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 9 of 68 LIST OF FIGURES  
Figure  5‒1:  Schematic of sequential cohort enrollment during the iv PK Period  ...............  18 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 10 of 68 LIST OF ABBREVIATION S 
AE adverse event  
AED  antiepileptic drug  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
bid twice daily  
BP blood pressure  
BRV  brivaracetam  
CDMS  clinical data management system  
CRF  Case Report form  
CRO  contract research organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
DMC  Data Monitoring Committee  
ECG  electrocardiogram  
GCP  Good Clinical Practice  
HLA  human leukocyte antigen  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IIB Initiating iv BRV  
IMP investigational medicinal product  
IOB Initiating Oral BRV  
IRB Institutional Review Board  
IRT interactive response technology  
iv intravenous  
MedDRA® Medical Dictionary for Regulatory Activities® 
OLB  Open -label BRV  
PCS possibly clinically significant  
PD pharmacodynamic(s)  
PDILI  potential drug -induced liver injury  
PK pharmacokinetic(s)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 11 of 68 PK-PPS PK Per -protocol Set  
POS partial -onset seizures  
PS Patient Safety  
q12h ±2h  every 12 hours ±2  hours  
RR respiratory rate  
RxB Prescribed -BRV  
SAE  serious adverse event  
SD standard deviation  
SOP standard operating procedure  
SS Safety Set  
SS-iv Safety Set -iv 
SV2A  synaptic vesicle protein 2A  
TC Telephone Contact  
ULN  upper limit of normal  
VNS  vagus nerve stimulation  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 12 of 68 1 SUMMARY  
EP0065 is a Phase 2, multicenter, open -label study with a primary objective of evaluating the 
pharmacokinetics (PK), safety, and tolerability of brivaracetam (BRV) administered as a 
15-minute intravenous (iv) infusion and an iv bolus (up to 2 -minute infusion) in subjects 
≥1 month to <16 years of age with epilepsy.  
The following subjects will be eligible for enrollment in  EP0065:  
 Open -label BRV (OLB) subjects: currently receiving oral BRV as participants in a 
long-term, open -label study  
 Prescribed -BRV (RxB) subjects: currently receiving prescribed oral BRV from commercial 
supply  
 Initiating Oral BRV (IOB) subjects: not curr ently receiving BRV; first dose of BRV in 
EP0065 will be oral tablet or solution  
 Initiating iv BRV (IIB) subjects: not currently receiving BRV; first dose of BRV in EP0065 
will be administered intravenously  
EP0065 includes the following consecutive periods : 
Subjects  Screening Period  
1 to 10 days  IOB Treatment 
Period  
2 to 10 days  iv PK Period  
1 to 6 days  
OLB  Oral BRV  Not applicable  iv BRV  
RxB Oral BRV  Not applicable  iv BRV  
IOB No BRV  Oral BRV  iv BRV  
IIB No BRV  Not applicable  iv BRV  
BRV=brivaracetam; IIB=Initiating iv BRV; IOB=Initiating Oral BRV; iv=intravenous; 
OLB=Open -label BRV; PK=pharmacokinetic RxB=Prescribed -BRV  
Note: Oral BRV will be administered as tablets or oral solution. Tablets will be administered 
orally, and oral solution will be admini stered either orally or by enteric administration (eg, 
feeding tube) based on subject need.  
During the Screening Period, OLB and RxB subjects will continue to receive oral BRV (tablet or 
oral solution) in accordance with their long -term, open -label study dosing or prescribed dosing, 
respectively. The IOB and IIB subjects will not receive BRV during the Screening Period.  
Eligible OLB, RxB, and IIB subjects will progress directly from the Screening Period to the 
iv PK Period, whereas IOB subjects will enter a 2- to 10 -day IOB Treatment Period in which 
they receive oral BRV before progressing to the iv  PK Period. The initial oral BRV dose in the 
IOB Treatment Period is 2mg/kg/day.  
During the iv  PK Period, iv BRV will be administered every 12 hours ±2  hours (q1 2h ± 2h). All 
subjects will receive 1 to 2 consecutive doses of BRV; however, based on medical need, subjects 
may receive up to 10  consecutive doses of iv BRV. Blood sampling for PK analyses (herein 
referred to as “PK sampling”) will occur with the first i v BRV administration and with 1  other iv 
BRV administration. For OLB, RxB, and IOB subjects, the first iv BRV dose will be equivalent 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 13 of 68 (mg-to-mg) to the final dose of oral BRV prior to the first iv dose. For IIB subjects, the first iv 
BRV dose will be 1mg/k g, not to exceed 50mg for subjects with body weights ≥50kg. For all 
subjects, iv BRV doses may be adjusted at the Investigator’s discretion after PK sampling for 
2 iv doses; however, no doses may exceed the maximum doses indicated below. During the 
iv PK P eriod, BRV may only be administered by iv infusion.  
At the completion of the iv  PK Period, subjects who will continue oral BRV treatment should 
enroll in a long -term, open -label BRV study. Subjects who have received ≥4 doses of BRV and 
do not plan to cont inue treatment with BRV after completion of the iv  PK Period or who 
discontinue BRV treatment during the study will have a Down -Titration Period of up to 4 weeks 
(28 days) for gradual discontinuation of BRV and a Safety (BRV -free) Period of 2  weeks 
(14 days) after the final dose of BRV. Subjects who have received <4 doses of BRV may have 
BRV down titrated at the discretion of the Investigator.  
For IOB and IIB subjects, the maximum BRV dose is 4mg/kg/day (2mg/kg twice daily [bid]). 
For OLB and RxB subjects, the maximum BRV dose is 5mg/kg/day (rounded) in recognition of 
the possibility that some of these subjects may be using this dose when they enter EP0065. 
Throughout the study, no subjects may receive a dose greater than BRV 200mg/day.  Oral 
BRV will be admi nistered in equally divided doses bid.  
It is planned for approximately 50 enrolled subjects to receive iv BRV in the following 
age-based cohorts (approximately 12  subjects/cohort), with approximately half of the subjects in 
each cohort receiving iv BRV as  a 15-minute (±3 minutes) infusion and half receiving iv BRV as 
a bolus (up to 2 -minute infusion).  
 Cohort 1: ≥12 to <16 years  
 Cohort 2: ≥6 years to <12 years  
 Cohort 3: ≥2 to <6  years  
 Cohort 4: 1  month to <2 years  
Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the 
first half will receive the 15 -minute infusion. The Data Monitoring Committee (DMC) will then 
meet to review safety and PK data, as available. After the DMC safety review, the remaining  half 
in that cohort will receive iv BRV as a bolus (up to 2 -minute infusion), and the next cohort may 
begin the 15 -minute infusion. Subjects may receive bolus infusions only after subjects in the 
preceding cohort have completed bolus infusions.  
The DMC will meet no  less than approximately every 6 months commensurate with enrollment.  
The PK variables are the plasma concentrations of BRV (parent compound only) before, during, 
and after the first and 1 subsequent administration of iv BRV.  
The primary safety variables  are adverse events (AEs) and withdrawals due to AEs. Other safety 
variables are clinical laboratory parameters (hematology, chemistry, and endocrinology), and 
urinalysis. Clinically significant new or worsened abnormalities discovered during physical and 
neurological examinations will be recorded as AEs. Other safety variables also include 12 -lead 
electrocardiogram (ECG), and vital signs (blood pressure [BP], pulse rate, respiratory rate [RR], 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 14 of 68 and temperature), all of which will be assessed with increased frequency during the iv  PK 
Period.  
The maximum study duration for an individual subject will be 68 days. Approximately 60  sites 
in Europe and North America are planned for participation in EP0065.  
2 INTRODUCTION  
Brivaracetam ((2S) -2-[(4R) -2-oxo-4-propyltetr ahydro -1H-pyrrol -1-yl]butanamide) displays a 
high and selective affinity for the synaptic vesicle protein 2A (SV2A) in the brain. Binding to 
SV2A is believed to be the primary mechanism for BRV anticonvulsant activity. In 2016, 
marketing authorization for the use of oral and iv BRV as adjunctive treatment of partial -onset 
seizures (POS) in patients was granted in the EU, US, and Australia for patients 16  years of age 
and older with epilepsy and in Canada for patients 18 years of age and older with epilepsy.  
Epilepsy affects all races of both sexes at any age from the first hour of life to extreme old age. 
The prevalence of epilepsy is 1% to 2% of the population and 4%  of pediatric population in 
those developed countries where they have been studied; this is probably double in resource -poor 
countries (Banerjee and Hauser, 2008). In the US, the overall incidence of epilepsy ranges from 
35.5 to 48 per 100,000 person -years and the prevalence ranges from 4.7 to 6.8 per 1000 
population (Theodore et al, 2006). The i ncidence of new -onset epilepsy in the pediatric 
population is 44.5 per 100,000 persons per year (Wirrell et al, 2011). Within the pediatric 
population, the incidence is highest in children <5 years of age (approximately 60 to 100 per 
100,000 person -years),  decreasing to approximately 25 to 45  per 100,000  person -years in 
adolescents and young adults (Wirrell et al, 2011; Hauser et al, 1993).  
In the US, 57% of newly diagnosed patients were classified as having POS (Zarrelli et al, 1999; 
Hauser et al, 1993). In the general population, the incidence of pediatric patients with epilepsy 
with POS is approximately 16 to 80 per 100,000 (Wirrell, et al, 2011; Banerjee and Hauser, 
2008; Hauser et al, 1993).  
The existing treatment options for POS in the pediatric popu lation generally follow the treatment 
options for adults with the same disorder; clinical experience demonstrates that children may 
have results comparable to adults with administration of the conventional antiepileptic drugs 
(AEDs). More than 25% of pedia tric patients have inadequate seizure control on currently 
available AEDs or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007). There remains a need for potent AEDs with a positive benefit -risk profile in this 
population.  
To da te, oral formulations of BRV have been studied in the ongoing BRV pediatric development 
program as follows:  
N01263 is a completed open -label, multicenter, fixed 3 -step up -titration, adjunctive therapy 
study of the PK, safety, and efficacy of BRV in 100 su bjects ≥1 month to <16 years of age 
with epilepsy. Doses of BRV (oral solution) were adjusted by body weight and did not 
exceed a maximum of 50mg/day, 100mg/day, and 200mg/day for each titration step. A total 
of 100 subjects enrolled in N01263: 99  subjects  received study drug and were included in the 
Safety Set. Results from N01263 indicate that BRV was generally well tolerated and that the 
safety profile in pediatric subjects was consistent with the known safety profile in adult 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 15 of 68 subjects. In general, there  were no clinically meaningful changes in laboratory parameters, 
vital signs, or ECG parameters. Trough plasma BRV concentrations increased proportionally 
to the dose.  
N01266 is an ongoing open -label, multicenter study to evaluate the long -term safety and  
efficacy of bid administration of BRV oral solution and oral tablets in pediatric subjects with 
epilepsy who are receiving ≥ 1 AED other than BRV; the maximum allowable BRV dose is 
5mg/kg/day not to exceed 200mg/day in subjects with body weights >40kg. N0 1266 was 
initially designed as a long -term follow -up to N01263, which enrolled only subjects with 
either focal epilepsy or generalized epilepsy but was amended to also allow direct enrollment 
of subjects 4 years to <17 years of age who have focal epilepsy.  Over 200  subjects have 
enrolled in N01266.  
In addition to oral formulations, iv formulations of AEDs are particularly helpful as short -term 
replacements when use of oral formulations is not possible or feasible (eg, pre and postoperative 
patients, patient s with acute gastrointestinal disorders, patients with acute swallowing disorders). 
Brivaractem injection has been approved for use as adjunctive therapy in the treatment of POS in 
patients 16 years of age and older with epilepsy and may be used when oral administration of 
BRV is temporarily not feasible. Treatment with BRV may be initiated with tablets, oral 
solution, or solution for injection.  
The current study, EP0065, is planned to evaluate the PK, safety, and tolerability of iv BRV 
administered as a 15 -minute infusion and bolus (up to 2 -minute infusion) in subjects ≥1 month to 
<16 years of age with epilepsy.  
The iv dose for subjects initiating BRV in this study was predicted in N01331, which modeled 
based on PK data from N01263 and N01256 (BRV adult st udy) and simulated the BRV iv 
concentrations in pediatric subjects. Based on the results of N01331, in the pediatric population 
1 month to <17 years of age, an iv injection 15 -minute infusion or bolus (up to 2 -minute 
infusion) of 4mg/kg/day (2mg/kg bid) re gimen (with a maximum of 200mg/day [100mg bid] for 
subjects with body weights ≥50kg) results in plasma concentrations in the same range as seen in 
adults receiving 200mg/day (100mg bid), the maximum recommended dose in adults with POS. 
These data support u sing a mg -to-mg equivalent to the oral dose for OLB and RxB subjects. As 
demonstrated in the concentration -effect analysis CL0258 using levetiracetam PK and 
pharmacodynamic (PD) data from adults and children and BRV PK and PD data in adults 
(N01358) and PK  data in children (N01263), in subjects 4 to 16  years of age, similar 
weight -normalized doses are needed to achieve the same efficacy as compared with adults, with 
a maximum response at 4mg/kg/day.  
More detailed information regarding the nonclinical and cl inical development programs for BRV 
is provided in the Investigator’s Brochure.  
3 STUDY OBJECTIVES  
The primary objective is to evaluate the PK, safety, and tolerability of BRV administered as a 
15-minute iv infusion and iv bolus (up to 2 -minute infusion) in subjects ≥1 month to <16 years 
of age with epilepsy.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 16 of 68 4 STUDY VARIABLES  
4.1 Pharmacokinetic variables  
 Plasma concentration of BRV (parent compound only) before, during, and after iv BRV 
administration  
4.2 Safety variables  
4.2.1  Primary safety variables  
 Adverse events throughout the study  
 Subject withdrawals due to AEs  
4.2.2  Other safety variables  
 12-lead ECG values before, during, and after each iv BRV administration  
 BP, pulse rate, RR, and temperature values before, during, and after each iv BRV 
administrat ion  
 Clinical laboratory parameters (hematology, chemistry, and endocrinology) pre and 
posttreatment  
 Urinalysis parameters pre and posttreatment  
5 STUDY DESIGN  
5.1 Study description  
EP0065 is a Phase 2 multicenter, open -label study to evaluate the PK, safety, an d tolerability of 
iv BRV administered as a 15 -minute iv infusion and an iv bolus (up to 2 -minute infusion) in 
subjects ≥1  month to <16  years of age with epilepsy.  
It is planned for approximately 50 enrolled subjects to receive iv BRV in the following 
age-based cohorts (approximately 12  subjects/cohort):  
 Cohort 1: ≥12 to <16 years  
 Cohort 2: ≥6 years to <12 years  
 Cohort 3: ≥2 to <6  years  
 Cohort 4: 1  month to <2 years  
The following subjects will be eligible for enrollment in EP0065:  
 OLB subjects: currentl y receiving oral BRV as participants in a long -term, open -label study  
 RxB subjects: currently receiving prescribed oral BRV from commercial supply  
 IOB subjects: not currently receiving BRV; first dose of BRV in EP0065 will be oral tablet 
or solution  
 IIB su bjects: not currently receiving BRV; first dose of BRV in EP0065 will be by iv 
infusion  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 17 of 68 For OLB and RxB subjects, the maximum BRV dose is 5mg/kg/day (rounded). For IOB and IIB 
subjects, the maximum BRV dose is 4mg/kg/day. Throughout the study, no subject m ay 
receive a dose greater than BRV 200mg/day. Subjects will receive oral BRV (tablets or oral 
solution) in equally divided doses; BRV oral solution may be given by enteric administration 
(eg, by feeding tube) based on subject need.  
The EP0065 study periods  and visits are described below. The PK assessments will be made 
during the iv  PK Period only and safety data will be collected throughout the study, with 
intensive collection of safety data with each iv BRV dose administered. A Schedule of Study 
Assessmen ts is provided for the Screening through iv  PK Periods in Table  5‒1 and for the 
Down -Titration Period and Safety (BRV -free) Periods (for subjects not c ontinuing BRV) in 
Table  5‒4. 
Screening Period (1 to 10 days)  
During the Screening Period, the OLB and RxB subjects will continue treatment with oral BRV 
using their assigned open -label study supply or prescribed commerci al supply, respectively. The 
IOB and IIB subjects will not receive BRV during this period.  
The OLB subjects will temporarily discontinue assessments in their long -term, open -label study 
when they enter EP0065. As such, all assessments for these subjects d uring the Screening Period 
(and subsequent periods of EP0065) will be recorded in the EP0065 Case Report form (CRF) 
until they return to a long -term, open -label study or discontinue BRV treatment.  
IOB Treatment Period (2 to 10 days of oral BRV treatment; f or IOB subjects only)  
Only IOB subjects who meet all eligibility criteria may participate in the IOB  Treatment Period. 
No other subjects may participate in this period.  
During the IOB  Treatment Period, IOB subjects will initiate treatment with oral BRV 
2mg/kg/day not to exceed 100mg/day for subjects with body weights ≥50kg and must have, at 
minimum, 2  days of treatment with oral BRV before entry into the iv  PK Period. Subjects who 
do not enter the iv PK Period will not be eligible for the long -term, open -label study.  
The Investigator is permitted to adjust the oral BRV dose during the IOB  Treatment Period in 
accordance with medical judgment (with a maximum dose of 4mg/kg/day, not to exceed 
200mg/day for subjects with body weights ≥50kg); however, subjects  must have no change in 
the oral BRV dose for the 2  days prior to entry into the iv  PK Period.  
iv PK Period (1 to 6 days, with Day  1 defined as the initial day of iv BRV infusion)  
During the iv  PK Period, iv BRV will be administered every 12 hours ±2  hours (q12h ± 2h). All 
subjects are to receive 1 to 2 consecutive doses of BRV; however, based on medical need, 
subjects may receive up to 10  consecutive doses of iv BRV. The PK sampling will occur with the 
first iv BRV administration and with 1  other iv BRV a dministration.  
The first dose  of iv BRV will be as follows:  
 OLB, RxB, and IOB subjects: mg -to-mg equivalent of the oral BRV dose immediately prior 
to the iv  PK Period; administered q12h ±2h after prior oral dose  
 IIB subjects: 1mg/kg not to exceed a maximu m of 50mg for subjects ≥50kg  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 18 of 68 After subjects have completed PK sampling with 2 iv BRV infusions, the Investigator may adjust 
the BRV dose, but the adjusted dose must not  exceed 5mg/kg/day (rounded) for OLB and RxB 
subjects and 4mg/kg/day for IOB and IIB sub jects (with the maximums not to exceed 
200mg/day). During the iv  PK Period, BRV may only be administered intravenously. Enrollment 
will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will 
receive the 15 -minute infu sion. The Data Monitoring Committee (DMC) will then meet to 
review safety and, as available, PK data ( Figure  5‒1). After the DMC safety review, the 
rema ining  half in that cohort will receive iv BRV as a bolus (up to 2 -minute infusion) and the 
next cohort may begin the 15 -minute infusion. Subjects may receive bolus infusions only after 
subjects in the preceding cohort have completed bolus infusions and the  DMC have reviewed 
these data. The DMC will meet no less than approximately every 6 months commensurate with 
enrollment.  
 
Figure  5‒1: Schematic of sequential cohort enrollment during the iv PK Period  
 
DMC=Data Monitoring Committee; inf=infusion; iv=intravenous; PK=pharmacokinetic  
Telephone Contact (TC) -1 will occur 1 to 3 days after completing the final iv BRV dose in the 
iv PK Period to facilitate reporting of infus ion-site related AEs.  
The schedules for PK sampling, 12 -lead ECGs, and vital sign assessments during the iv  PK 
Period are provided in Table  5‒2 (15-minute infusion), and Table  5‒3 (bolus [up to 2 -minute 
infusion]).  
Down -Titration Period (up to 4 weeks) and Safety (BRV -free) Period (2 weeks)  
Subjects wh o receive ≥4 doses of BRV during either the IOB  Treatment Period or the iv  PK 
Period and who do not plan to continue treatment with BRV or who discontinue from the study 
will enter a Down -Titration Period. Subjects who have received <4 doses of BRV may hav e 
BRV down titrated at the discretion of the Investigator. During the Down -Titration Period, 
subjects will have their BRV dose reduced by a maximum of half the dose every week for a 
maximum of 4 weeks until a dose of 1mg/kg/day (50mg/day for subjects with body weights 
≥50kg) is reached. Subjects not able to receive oral BRV for down titration, may receive iv BRV 
for down titration. In the latter circumstance, the subjects may receive more than 10  consecutive 
>12 years to < 16 years
>6 years to <12 years
>2 years to <6 years15 min inf bolus
15 min inf bolus
15 min inf bolusN 12
N 12
N 12
N 12>1 month to <2 years
bolus 15 min infDMC
DMC DMCDMC
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
 
Confidential  Page 19 of 68 doses of iv BRV in accordance with the Investigat or’s discretion. A 2 -week Safety (BRV -free) 
Period will follow the final dose of BRV.  
Safety assessments will be collected throughout this period  (Table  5‒4). 
5.1.1  Study duration per subject and definition for start/end of study  
The maximum possible study duration is 68  days and the maximum period of BRV 
administration is 44  days including a minimum of 1  dose of iv BRV.  
The start of the study is defined as the  date the first Informed Consent form (ICF)/Assent form is 
executed. The end of the study is defined as the date of the last visit of the last subject enrolled.  
5.1.2  Planned number of subjects and sites  
It is planned for approximately 50 enrolled subjects to re ceive iv BRV. Approximately 60  sites 
are planned.  
5.1.3  Anticipated regions and countries  
Approximately 60  sites in Europe and North America are planned for participation in EP0065.  
5.2 Schedule of study assessments  
A schedule of study assessments for the Screening  Period through the iv  PK Period is provided 
in Table  5‒1, with detailed schedules for PK sampling, ECG, and vital sign assessments during 
the iv  PK Pe riod provided in Table  5‒2 (15-min infusion) and Table  5‒3 (bolus [up to 2 -minute 
infusion]).  
A schedule of study assessment for subjects who will not continue BRV is provided in Table  5‒4 
(Down -Titration and Safety [BRV -free] Periods).  
Note , possibly  clinically significant (PCS) vital sign values are defined as those PCS values 
which occur at any time  during the study. Only BP  to be collected at 2 hours post initiation of 
infusion.  Additional vital sign monitoring, specifically  BP is necessary if a low PCS  BP value 
occurs at 2 hours after the start of an infusion.  Subjects should not be provided iv BRV if the 
latest <1 -hour pre -initiation measurement of systolic or diastolic BP is a low PCS value.  In this 
case BP measurements should be repeated and the iv BRV infusion be started only after the BP 
does not meet the low PCS criterion anymore . The criteria for BP values to be low or high PCS 
values are described in Table  10-6. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 20 of 68 Table  5‒1: Schedule of Study Assessments (Screening Period through end of iv  PK Period)  
Period  Screening  IOB Treatment  iv PK   Unscha 
Visit  V1 V2 V3 to V12  TC-1  
Study Day for       
OLB, RxB, IIB 
subjects  -10 to -1 N/A 1 to 6 2 to 9  N/A 
IOB subjects  -20 to -11 -10 to -1    
Assessments       
Informed consent/as applicable, Assent form  X     
Subject identification card dispensing  X     
Inclusion/exclusion criteria  X Xb Xb   
Demographic data  X     
General medical/procedure history  X     
Historical seizure count  X     
Prior/concomitant medications including AEDs  X X X X X 
Physical examinationc X  Xe   
Tanner stagingd   Xb   
Neurological examinationc X  Xe   
Body weightf X Xb Xb   
Body height  X  X   
Vital signs (BP, pulse rate, RR, temperature) X X Xg  X 
12-lead ECG  X  Xg   
Clinical chemistry, hematology, and endocrinology X     
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 21 of 68 Table  5‒1: Schedule of Study Assessments (Screening Period through end of iv  PK Period)  
Period  Screening  IOB Treatment  iv PK   Unscha 
Visit  V1 V2 V3 to V12  TC-1  
Study Day for       
OLB, RxB, IIB 
subjects  -10 to -1 N/A 1 to 6 2 to 9  N/A 
IOB subjects  -20 to -11 -10 to -1    
Urinalysis  
(for subjects for whom sample collection is feasible)  X     
Pregnancy testing (urine; for females of CB potential)  X X Xb   
AEsh X X X X X 
Withdrawal criteria   X X X X 
C-SSRSi X X Xj  Xk 
PK sampling    Xg   
Dispense/collect oral BRV from EP0065 supply   X Xl   
Administration of iv BRV    X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 22 of 68 Table  5‒1: Schedule of Study Assessments (Screening Period through end of iv  PK Period)  
Period  Screening  IOB Treatment  iv PK   Unscha 
Visit  V1 V2 V3 to V12  TC-1  
Study Day for       
OLB, RxB, IIB 
subjects  -10 to -1 N/A 1 to 6 2 to 9  N/A 
IOB subjects  -20 to -11 -10 to -1    
AE=adverse event; AED=antiepileptic drug; BP=blood pressure; BRV=brivaracetam; CB=childbearing; CRF=Case Report form; C -SSRS=Columbia -Suicide 
Severity Rating Scale; ECG=electrocardiogram; IIB=Initiating iv BRV; IOB=Initiating Oral BRV; iv=intravenous; N/A=not applica ble; OLB=Open -label BRV; 
PK=pharmacokinetic; RR=re spiratory rate; RxB=Prescribed BRV; TC=Telephone Contact; Unsch=Unscheduled; V=Visit  
a Additional assessments may be performed at the Investigator’s discretion.  
b To be performed prior to dispensing/administering the initial dose of BRV in this period (fo r the PK Period, at Visit 3 only).  
c Complete examinations should be conducted at Visit 1. Brief physical and neurological examinations should be conducted at oth er designated visits. Clinically new 
or worsened abnormalities must be reported as AEs.  
d The Investigator should use clinical judgment in deciding which subjects are selected for evaluation of Tanner Stage (ie, those s ubjects who are pubescent).  
e To be performed prior to the initial dose of BRV (Visit 3) and daily thereafter, ideally after the morning dose.  
f Body weight determinations should be made with subjects wearing light clothing and not wearing shoes.  
g Detailed timings for these assessments are provided in Table  5‒2 (15-minute [ ±3 minutes] infusion) and Table  5‒3 (bolus [up to 2 -minute infusion]).  
h Infusion -site related AEs for subj ects who have returned to/entered a long -term, open -label study should continue to be recorded in the EP0065 CRF.  
i The C -SSRS will be assessed only in subjects ≥6 years of age. The C -SSRS versions to be used are specified in Section  10.3.3 .  
j To be assessed prior to the administration of iv BRV at Visit 3 and after the final iv dose of BRV each day for Visits 4 to 1 2, as applicable.  
k The C -SSRS will be assessed only in subjects who attend this visit due to safety reasons.  
l To be collected as needed for IOB subjects who will enter the long -term, open -label study. To be dispensed, as needed, for subjects continuing into the 
Down -Titration Period a t the final visit of the PK Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 23 of 68 Table  5‒1: Schedule of Study Assessments (Screening Period through end of iv  PK Period)  
Period  Screening  IOB Treatment  iv PK   Unscha 
Visit  V1 V2 V3 to V12  TC-1  
Study Day for       
OLB, RxB, IIB 
subjects  -10 to -1 N/A 1 to 6 2 to 9  N/A 
IOB subjects  -20 to -11 -10 to -1    
Table  5‒2: Schedule for iv  PK Period ECGs, vital signs, and PK sampling (15 -min BRV infusion)  
 Time relative to initiation of iv BRV infusion  
 Pre-initiation  Post-initiation  
 
Assessment  ≤ 1hr  
 5min  
(±1min)  10min  
(±1min)  15mina 
(±2min)  30min  
(±5min)  60min  
 (±10min)  2hr 
 (±15min)  3hr 
(±15min) 
12-lead ECG  X X X X X X X  
Vital signs  
(BP, pulse rate, RR, temperature)  X X X X X X Xc  
PK samplingb X   X    X 
BP=blood pressure; BRV=brivaracetam; ECG=electrocardiogram; hr=hour(s); min=minute(s); iv=intravenous; PK=pharmacokinetic;  PCS=possibly clinically 
significant;  RR=respiratory rate  
a To be conducted at the end of infusion.  
b Blood samples for PK analyses will be collected for the initial BRV infusion and 1 subsequent BRV infusion only. Blood samples shou ld be collected after 
completion of the ECG and the vital sign measurements and from a region of the body not used for iv the BRV a dministration.  
c Only BP to be collected at 2 hours post initiation of infusion. Additional vital sign monitoring , specifically BP is necessary if a  low PCS BP value occurs at 2 hours 
after the start of an infusion.   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 24 of 68 Table  5‒3: Schedule for iv  PK Period ECGs, vital signs, and PK sampling (bolus [up to 2 -min BRV infusion])  
 Time relative to initiation of iv BRV administration  
 Pre-
initiation  Post-initiation  
 
Assessment  ≤ 1hr  
 ≤ 2mina 
 5min  
(±1min)  
 15min  
(±2min)  
 30min  
(±5min)  
 60min  
 (±10min)  2hr 
 (±15min)  3hr 
(±15min) 
12-lead ECG  X X X X X X X  
Vital signs  
(BP, pulse rate, RR, temperature) X X X X X X Xc  
PK samplingb X   X    X 
BP=blood pressure; BRV=brivaracetam; ECG=electrocardiogram; hr=hour(s); min=minute(s); iv=intravenous; PK=pharmacokinetic; PCS=possibly clinically 
significant; RR=respiratory rate  
a To be conducted during bolus/infusion, if feasible.  
b Blood samples for PK analyses will be collected for the initial BRV infusion and 1 subsequent BRV infusion only. Blood samples shou ld be collected after 
completion of the ECG and the vital sign measurements and from a region of the body not used for the iv BRV a dministration.  
cOnly BP to be collected at 2 hours post initiation of infusion.  Additional  vital sign monitoring, specifically BP is necessary if a low PCS BP value occurs at 2 
hours after the start of an infusion.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 25 of 68 Table  5‒4: Schedule of study assessments for Down -Titration and Safety (BRV -free) Periods (subjects not 
continuing into the Long ‑Term, Open ‑Label Study)  
 Down -Titration  Safety (BRV -free)  
Visit  TC-2a V13 TC-3b 
Assessments     
Concomitant medications including AEDs  X X X 
Physical examination (brief)   X  
Neurological examination (brief)   X  
Body height   X  
Vital signs (BP, pulse rate, RR, temperature)   X  
12-lead ECG   X  
Clinical chemistry, hematology, and endocrinology   X  
Urinalysis  
(for subjects for whom sample collection is feasible)   X  
Pregnancy testing (urine; for females of CB potential)   X  
AEs X X X 
Withdrawal criteria  X   
C-SSRSc  X  
Collect oral BRV   X  
AEDs=antiepileptic drug; AEs=adverse events; BP=blood pressure; BRV=brivaracetam; CB=childbearing; C -SSRS=Columbia -Suicide Severity 
Rating Scale; ECG=electrocardiogram; RR=respiratory rate; TC=telephone contact; V=Visit  
a This TC is only applicable to subjects with a Down -Titration Period of more than 2 weeks. The TC should be conducted approximately half way 
through the Down -Titration Period.  
b This TC is only applicable for subjects who have attended Visit 13 and will be conducted approximately 2 weeks after the fina l dose of BRV.  
c The C -SSRS will be assessed only in subjects ≥6 years of age. The C -SSRS versions to be used are specified in Section  10.3.3 . 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 26 of 68 5.3 Rationale for study design and selection of dose  
In 2016, marketing authorization for the use of oral and iv BRV as adjunctive therapy in the 
treatment of POS was granted in the in the EU, US, and Australia for patients 16 years of age 
and older  and in Canada for patients 18  years of age and older with epilepsy. The recommended 
starting dosing of BRV is 50mg bid. Based on individual patient tolerability and therapeutic 
response, the dosage may be adjusted down to 25mg bid (50mg/day) or up to 100m g bid 
(200mg/day). Brivaracetam injection can be administered intravenously over 2 to 15 minutes 
when oral administration of BRV is temporarily not feasible. Pharmacokinetic data for BRV 
administered by the oral route are available over the age range from adults down to 1 month of 
age and have demonstrated that BRV is completely absorbed and fully bioavailable orally. In 
adults, BRV iv bolus and oral tablet are bioequivalent.  
Brivaracetam injection was evaluated in N01258, an open -label, multicenter study evaluating the 
safety and tolerability of BRV 200mg/day administered for 4.5  days as a 15 -minute iv infusion 
or a 2 -minute iv bolus in subjects ≥16 to 70 years of age with epilepsy. Results from N01258 
indicated that iv BRV (as both 15 -minute infusion and 2-minute bolus) was well tolerated. The 
AE profile was similar regardless of whether iv BRV was administered as a 2 -minute bolus or a 
15-minute infusion. Given these results in older subjects ≥16 years, it is expected that BRV will 
have similar results in younger subjects aged ≥1 month to <16 years of age.  
The PK, safety, and efficacy of BRV in 100 subjects aged ≥1 month to <16 years with epilepsy 
were evaluated in N01263, an open -label, multicenter, fixed 3 -step up -titration, adjunctive 
therapy study using  an oral solution formulation. All doses were adjusted by body weight and did 
not exceed a maximum of 50mg/day, 100mg/day, and 200mg/day for each titration step. Results 
from N01263 indicated that BRV was generally well tolerated and that the safety profil e in 
subjects aged ≥1 month to <16 years was consistent with the known safety profile in adults. 
Trough plasma BRV concentration increased proportionally to BRV dose.  
The iv dose for subjects initiating BRV in this study was predicted in N01331, which mode led 
based on PK data from N01263 and N01256 (BRV adult study) and simulated the BRV iv 
concentrations in pediatric subjects. Based on the results of N01331, in the pediatric population 
1 month to <17 years of age, an iv injection 15 -minute infusion or bolu s (up to 2 -minute 
infusion) of 4mg/kg/day (2mg/kg bid) regimen with a maximum of 200mg/day (100mg bid) 
results in plasma concentrations in the same range as seen in adults receiving 200mg/day (100mg 
bid), the maximum recommended dose in adults with POS. Th ese data support using a mg -to-mg 
equivalent to the oral dose for OLB and RxB subjects. As demonstrated in the 
concentration -effect analysis CL0258 using levetiracetam PK and PD data from adults and 
children and BRV PK and PD data in adults (N01358) and PK  data in children (N01263), in 
subjects 4 to 16  years of age, similar weight -normalized doses are needed to achieve the same 
efficacy as compared with adults, with a maximum response at 4mg/kg/day.  
EP0065 has been designed to evaluate the PK, safety, and t olerability of iv dosing of BRV in 
subjects 1  month to <16  years of age, as iv formulations are particularly helpful as short -term 
replacement of oral formulations for patients unable to take oral products (eg, pre and 
postoperative patients, patients with  acute gastrointestinal disorders). For OLB and RxB subjects, 
the maximum BRV dose is 5mg/kg/day (rounded) to allow for the possibility that these subjects 
enter EP0065 on this dose. Dose selection for IOB and IIB subjects was based on the results 
obtained  in N01331 and the recommended dose of BRV as adjunctive therapy in the treatment of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 27 of 68 POS in patients 16 years of age and older with epilepsy. For IOB and IIB subjects, the starting 
BRV dose (2mg/kg/day [1mg/kg bid]) and maximum BRV dose (4mg/kg/day [2mg/kg  bid]) in 
subjects with body weights <50kg approximate the 100mg/day (50mg bid) starting dose and 
200mg/day (100mg bid) maximum dose recommended for use in adults. No subjects enrolled in 
EP0065 are permitted have a dose that exceeds a maximum of 200mg/day  (100mg bid) as 
consistent with the maximum recommended dose.  
6 SELECTION AND WITHDR AWAL OF SUBJECTS  
6.1 Inclusion criteria  
To be eligible to participate in this study, all of the following criteria must be met:  
1. Subject or the parent(s) or legal representative o f the subject has signed and dated an 
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
ICF. The ICF or a specific Assent form, where required, will be signed and dated by minors.  
2. The Investigator considers the subject/le gal representative to be reliable and able to comply 
with all study requirements.  
3. Subject is male or female from ≥1 month to <16 years of age. For subjects who are <1  year 
from birth and who were preterm infants, the corrected gestational age should be us ed for this 
entry requirement. The corrected gestational age is calculated by subtracting the number of 
weeks born before 37 weeks of gestation from the chronological age.  
4. Subject weighs ≥3kg (6.6lbs).  
5. Subject has a diagnosis of epilepsy.  
6. Subject is an acc eptable candidate for venipuncture and iv infusion.  
7. Subject being treated with ≥1 AED (including BRV) without a change of dose regimen for at 
least 7  days prior to Screening.  
8. Subject is not being treated with vagus nerve stimulation (VNS), OR the subject i s being 
treated with VNS and the settings have been constant for ≥ 7 days prior to Screening.  
9. For female subjects, the subject is  
 Not of childbearing potential  
-OR- 
 Of childbearing potential, and  
 Is not sexually active  
 Has a negative pregnancy test  
-OR- 
 Of childbearing potential, and  
 Is sexually active  
 Has a negative pregnancy test  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 28 of 68  Understands the consequences and potential risks of inadequately protected sexual 
activity, understands and properly uses contraceptive methods, and is willing to inform 
the Investigator of any contraception changes. Medically acceptable contraceptive 
methods for the study include, but are not limited to:  
 Oral or depot contraceptive treatment with at least ethinylestradiol 30µg per intake or 
ethinylestradiol 50µg per intake if also taking one of the following: carbamazepine, 
phenobarbital, primidone, phenytoin, oxcarbazepine, St. John's Wort, or rifampicin,  
 Barrier contraception: Intra Uterine Device, diaphragm with spermicide, male or 
female condom with spermicide   
 Abstinence  from sexual intercourse  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Subject has previously received iv BRV in this study.  
2. Subject is pregnant or nursing.  
3. Subject has any medical, neurolog ical, or psychiatric condition that, in the opinion of the 
Investigator, could jeopardize the subject’s health or compromise the subject’s ability to 
participate.  
4. Subject is being treated with BRV at a dose >5mg/kg/day (rounded) or >200mg/day for 
subjects with body weights >40kg.  
5. Subject requires or is likely to require a change in concomitant AED(s), dose of concomitant 
AED(s), or formulation of AED(s) during the 7 days prior to the iv  PK Period.  
6. Subject is likely, in the opinion of the Investigator, to re quire rescue medication during the 
IOB Treatment or iv  PK Periods.  
7. Subject is ≥6 years of age and has a lifetime history of suicide attempt (including an actual 
attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 month s 
as indicated by positive responses (“Yes”) to either Question 4 or Question 5 of the 
Columbia -Suicide Severity Rating Scale (C -SSRS) at Screening.  
8. Subject is participating in a long -term, open -label BRV study and meets any of the must 
withdraw criteria f or that study.  
9. Subject has any medical condition that could reasonably be expected to interfere with the 
absorption, distribution, metabolism, or excretion of BRV.  
10. Subject has a clinically relevant ECG abnormality, in the opinion of the Investigator.  
11. Subject has experienced generalized convulsive status epilepticus in the 28  days prior to 
Screening or during the Screening Period.  
12. Subject has a known hypersensitivity to a pyrrolidone derivative(s) or any of the components 
of the oral or iv formulations of BRV.  
13. Subject has a history of severe adverse hematologic reaction to any drug.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 29 of 68 14. Subject has >1.5x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN t otal bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the CRF.  
If subject has >ULN ALT, AST, or ALP that does n ot meet the exclusion limit at Screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medi cal Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re -screening.  
15. Subject has chronic liver disease.  
6.3 Withdrawal criteria  
Subjects are free to withdraw from the study a t any time, without prejudice to their continued 
care. The following criteria for subject withdrawal from EP0065 are outlined below. Additional 
discontinuation criteria for potential drug -induced liver injury are presented in Section  6.3.1 . 
Subjects must  be withdrawn from the study if any of the following events occur:  
1. Subject experiences intolerable AEs and AEs associated with BRV administration that,  in the 
opinion of the Investigator, precludes further participation in this study.  
2. Sponsor or a regulatory agency requests withdrawal of the subject.  
3. Subject becomes pregnant during the study, as evidenced by a positive pregnancy test.  
4. Subject is unwillin g or unable to continue, or the parent/legal guardian is unwilling or unable 
to allow the subject to continue in this study.  
5. Investigator decides that withdrawal from further participation would be in the subject’s best 
interest.  
6. For subjects ≥6 years of a ge, subject has active suicidal ideation with a specific plan as 
indicated by a positive response (“Yes”) to Question  5 of the “Since Last Visit” version of 
the C -SSRS. The subject should be referred immediately to a Mental Healthcare Professional 
and must  be withdrawn from the study.  
Participation in this study may be discontinued for any of the following reasons:  
7. Subject experiences generalized convulsive status epilepticus.  
8. Subject has any clinically relevant change in medical or psychiatric condition (if in the 
opinion of the Investigator, the change in condition warrants discontinuation from this study).  
9. Subject takes prohibited concomitant medications as defined in this protocol ( Section  7.8.2 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 30 of 68 10. Subject and/or delegated caregiver is noncompliant with study procedures or medication, in 
the opinion of the Investigator.  
11. For subjects ≥6 years of age, subject has active suicidal ideation without a sp ecific plan as 
indicated by a positive response (“Yes”) to Question 4 of the “Since Last Visit” version of C -
SSRS. The subject should be referred immediately to a Mental Healthcare Professional and 
may be withdrawn from the study based upon the Investigato r’s judgment of benefit/risk of 
continuing the subject in the study/on study medication.  
 Investigators should attempt to obtain information on subjects in the case of withdrawal; 
subjects who withdraw from the study without down titration of BRV should com plete the 
Visit 13 ( Table  5‒4). 
For subjects considered lost to follow up, the Investigator should make an effort (at least 1 phone 
call and 1 written mes sage to the subject), and document his/her effort (date and summary of the 
phone call and copy of the written message in the source documents), to complete the final 
evaluation. All results of these evaluations and observations, together with a narrative d escription 
of the reason(s) for removing the subject, must be recorded in the source documents. The CRF 
must document the primary reason for withdrawal.  
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a sub ject in advance.  
6.3.1  Potential drug -induced liver injury investigational medicinal product 
discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if the 
investigational medicinal product (IMP) must be discontinued. In addition, all concomitant 
medications and herbal supplements that are not medically necessary sh ould also be 
discontinued.  
The PDILI criteria below require immediate and permanent discontinuation of IMP:  
 Subjects with either of the following:  
 ALT or AST ≥5xULN  
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requir es immediate discontinuation of IMP:  
 Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivit y symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator.  
 Subjects with ALT or AST ≥3xULN (and ≥2x baseline) and <5x ULN,  total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 31 of 68 Evaluation of PDILI must be initiated as described in Section  10.2.1 . If subjects are unable to 
comply with the applicable monitoring schedule , IMP must be discontinued immediately.  
Investigators should attempt  to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observa tions, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.  
7 STUDY TREATMENT(S)  
7.1 Description of investigational me dicinal products  
Information pertaining to excipients and tablet coatings for the IMP used in this study is 
provided in the Investigator’s Brochure.  
7.1.1  Film-coated tablets for oral administration  
Tablet strengths: BRV 10mg, 25mg, 50mg, 75mg, and 100mg  
7.1.2  Oral s olution  
Concentration: BRV 10mg/mL  
7.1.3  Solution for iv injection  
Concentration: BRV 10mg/mL  
7.2 Treatments to be administered  
For BRV tablets, the mg dosage for the oral tablet treatment should be calculated to match as 
closely as possible the mg/kg based dosage.  Tablets of BRV 10mg, 25mg, 50mg, 75mg, and 
100mg are supplied and may be combined, as needed, to achieve the calculated mg/kg dose. 
Tablets and solution must not be used together to comprise an individual dose.  
The dose of oral solution will be measured u sing the appropriate syringes (1mL, 3mL, and/or 
10mL) with an adaptor able to fit the bottle sizes. Oral solution should not be mixed with other 
liquids prior to administration.  
For 15 -min iv infusions, a calibrated infusion pump should be used for delive ring the iv BRV 
dose at a constant rate over the target duration assigned. A previously unused vial must be 
administered for each dose. Dilution is not required prior to administration of iv BRV. The BRV 
solution for iv injection can be diluted as needed i n any of the following diluents:  
 0.9% sodium chloride injection  
 Lactated Ringer’s injection  
 5% dextrose injection  
The total volume of diluent should be calculated not to exceed a total volume of fluid intake/day 
based on the Holliday -Segar equation as follows:  
 For children weighing ≤10kg: 100mL/kg body weight  
 For children weighing >10 to ≤20kg: 1000mL + 50mL/kg for e ach kg body weight ≥10kg  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 32 of 68  For children weighing ≥20kg: 1500mL + 20mL/kg for each kg body weight ≥20kg  
Brivaracetam will be dispensed using interactive response technology (IRT).  
7.2.1  Screening, IOB Treatment, and iv PK Periods  
Dosing information for BRV during t he Screening, IOB Treatment, and iv  PK Periods is 
provided in  Table  7‒1.  
Table  7‒1: BRV dosing during the Screening, IOB Treatment, and iv  PK Periods  
 Study Period   
 Screening  
(1-10 days)  IOB Treatment  
(2-10 days)a iv PK  
(1-6 days)b  
Subjects  Dose (oral)  Dose (oral)  First dose 
(iv) Subsequent 
dose(s) (iv)  Maximum BRV 
Dose  
OLB  Per 
Long -Term, 
Open -Label 
study  N/A mg-to-mg 
equivalent to 
last oral dose  Equivalent to 
first iv dose 
until PK 
sampling is 
completed.  5mg/kg/day 
(rounded) nte. 
200mg/day for body 
weight ≥40kg  
RxB As prescribed  N/A mg-to-mg 
equivalent to 
last oral dose  Equivalent to 
first iv dose 
until PK 
sampling is 
completed.  5mg/kg/day  
(rounded) nte. 
200mg/day for body 
weight ≥40kg  
IOB Not receiving 
BRV  Subjects <50kg: 
2mg/kg/day  
 
Subjects ≥50kg: 
nte. 100mg/day  mg-to-mg 
equivalent to 
last oral dose  Equivalent to 
first iv dose 
until PK 
sampling is 
completed.  4mg/kg/day  
nte. 200mg/day for 
body weight ≥50kg  
IIB Not receiving 
BRV  N/A Subjects 
<50kg: 
1mg/kg  
Subjects 
≥50kg:  
50mg  Equivalent to 
first iv dose 
until PK 
sampling is 
completed.  4mg/kg/day nte. 
200mg/day for body 
weight ≥50kg  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 33 of 68  Study Period   
 Screening  
(1-10 days)  IOB Treatment  
(2-10 days)a iv PK  
(1-6 days)b  
Subjects  Dose (oral)  Dose (oral)  First dose 
(iv) Subsequent 
dose(s) (iv)  Maximum BRV 
Dose  
bid=twice daily; BRV=brivaracetam; IIB=Initiating iv BRV; IOB=Initiating Oral BRV; iv=intravenous; 
LT=Long -term; N/A=not applicable; nte.=not to exceed; OL=Open -label; OLB=Open -label BRV; 
PK=pharmacokinetic; q12h=every 12 h ours; RxB=Prescribed BRV  
Note: Oral BRV will be administered in equally divided doses bid as either tablets or oral solution. Tablets will be 
administered orally and oral solution will be administered either orally or by enteric administration (eg, feeding  
tube) based on subject need.  
Note: Intravenous BRV will be administered as a 15 -minute ( ±3 minutes) infusion or bolus (up to 2 -minute 
infusion), as assigned and will be administered q12hours ± 2 hours.  
a Dose adjustment is allowed at the Investigator’s di scretion provided the adjusted dose does not exceed the 
maximum dose indicated in the rightmost column of this table and does not occur within 2 days of entry into the 
iv PK Period.  
b Dose adjustment is allowed at the Investigator’s discretion provided tha t PK sampling has been completed for 
2 doses and the adjusted dose does not exceed the maximum dose indicated in the rightmost column of this table 
and does not occur within 2 days of entry into the iv  PK Period.  
7.2.2  Down -Titration Period  
All subjects who have received ≥4 doses of BRV during either the IOB  Treatment Period or the 
iv PK Period and who will not continue BRV will have their BRV dose reduced by a maximum 
of half the dose every week for a maximum of 4 weeks until a dose of 1mg/kg/day (50mg for 
subjects with body weights ≥50kg) is reached. Subjects who have received <4 doses of BRV 
may have BRV down titrated at the discretion of the Investigator. Subjects not able to receive 
oral BRV for down titration, may receive iv BRV for down titration. In th e later circumstance, 
the subjects may receive more than 10  consecutive doses of iv BRV in accordance with the 
Investigator’s discretion.  
The OLB subjects who discontinue BRV during the Screening Period will return to the 
long-term, open -label study for do wn titration of BRV.  
7.3 Packaging  
Primary packaging:  
 Tablets for oral administration: high -density polyethylene bottles with child -resistant closure 
containing tablets of BRV 10mg, 25mg, 50mg, 75mg, and 100mg  
 Oral solution: 300mL amber glass bottles with chi ld-resistant closure  
 Solution for iv injection: 6mL clear Type I glass vials with bromobutyl rubber stopper 
containing 5mL (50mg) of BRV  
7.4 Labeling  
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any locally required statements. If necessary, labels will be translated 
into the local language.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 34 of 68 7.5 Handling and storage requirements  
The Investigator (or desig nee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label. Additional 
information pertaining to the handling of BRV, a Schedule V drug, is provided in the IMP 
Handling Manual.  
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg,  once a week), showing actual and minimum/maximum temperatures 
reached over the time interval.  
In case an out -of-range temperature is noted, it must be immediately reported as per instruction s 
contained in the IMP Handling Manual.  
7.6 Drug accountability  
A Drug Accountability form will be used to record IMP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the Sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed, taking into account local laws and regulations.  
The Invest igator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged and/or expired IMP containers must be reconciled 
and either destroyed at the site according to local laws, regulations, and UCB standard op erating 
procedures (SOPs), or returned to UCB (or designee). Investigational medicinal product intended 
for the study cannot be used for any other purpose than that described in this protocol.  
7.7 Procedures for monitoring subject compliance  
At each visit afte r IMP is dispensed, subjects/guardians must return all unused IMP and empty 
IMP containers. Drug accountability must be done in the subject’s presence in order to obtain 
explanations regarding discrepancies in compliance with the dosing regimen. Drug 
accou ntability must be recorded on the Drug Accountability form.  
Site personnel who are administering iv BRV will record information about all doses 
administered, including the target dose, actual dose administered, and the dates and times of 
initiation and com pletion of each iv administration. If the actual dose is less or more than the 
target dose, the reason a partial or excessive dose was administered will be recorded.  
Intravenous solution will be administered under supervision of the Investigator or his/he r 
designee. The noninjected volume will be recorded in the CRF. Compliance with the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 35 of 68 recommended duration of the iv administration will also be assessed by recording the start time 
and the stop time in the CRF.  
Subjects who receive <75% or >125% of the pla nned BRV dose will be considered 
noncompliant. If a subject is found to be persistently noncompliant in the Investigator’s opinion, 
the Sponsor, in conjunction with the Investigator, will make a decision as to whether the subject 
should be withdrawn from t he study.  
7.8 Concomitant medication(s)/treatment(s)  
For any treatment other than the IMP, including over -the-counter products, an accurate record 
must be kept in the clinic chart (source documentation) and in the CRF. Concomitant 
medications should be recorde d on the concomitant AED page or the concomitant non AED 
medication page of the CRF, according to the indication. New medications should be recorded in 
the CRF at only the first visit at which they are reported and subsequently only if there is a 
change. F or any change, the start date corresponding to the date of change in administration 
should be recorded in the CRF.  
7.8.1  Permitted concomitant treatments (medications and therapies)  
All treatments are permitted with the exception of those listed in Section 7.8.2 .  
Vagus nerve stimulation is allowed and will be counted as a concomitant AED. A stable 
ketogenic diet is allowed.  
7.8.2  Prohibited concomitant treatment s (medications and therapies)  
The following concomitant medication is prohibited during the study:  
 Levetiracetam  
7.8.3  Rescue medication  
Investigators may administer rescue medication in accordance with medical judgment at any 
time during the study. No rescue me dication will be supplied by UCB.  
7.9 Blinding  
This is an open -label study; no blinding is required.  
7.10 Randomization and numbering of subjects  
Subjects will not be randomized in EP0065.  
For OLB subjects, the unique identification number assigned to them in the open -label study will 
be used to identify them and maintain subject confidentiality throughout EP0065.  
The RxB, IOB, and IIB subjects will be assigned a unique identification number for 
identification and to maintain subject confidentiality. To enroll the se subjects, the Investigator or 
designee will contact the IRT and provide brief details about the subject to be enrolled. Each 
subject will receive a 5 -digit number assigned at screening that serves as the subject identifier 
throughout the study. The subj ect number will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject. Subject numbers and kit 
numbers will be tracked via the IRT.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 36 of 68 8 STUDY PROCEDURES BY VISIT  
Days are provided relative to Day 1, t he first day of the iv  PK Period.  
8.1 Visit 1 (Day -10 to Day -1 for OLB, RxB, and IIB subjects; Day  -20 
to Day  -11 for IOB subjects)  
 Signing and dating of written ICF by parent(s)/legal representative(s)  
 Signing and dating of Assent form by the subject (if applicable, according to age and local 
requirements)  
The following assessments should be performed only after the ICF and Assent form (if 
applicable) procedures described immediately above are completed:  
 Subject identification card dispensing  
 Inclusion/ex clusion criteria  
 Demographic data  
 General medical/procedure history  
 Historical seizure count  
 Prior and concomitant medications including AEDs  
 Physical examination (complete)  
 Neurological examination (complete)  
 Body weight (before BRV dispensed)  
 Body height  
 Vital signs (BP, pulse rate, RR, and temperature)  
 12-lead ECG  
 Clinical chemistry, hematology, and endocrinology  
 Urinalysis for subjects for whom urine sample collection is feasible  
 Pregnancy testing for females of childbearing potential (urine test)  
 AEs  
 C-SSRS (for subjects ≥6 years of age); version per Section  10.3.3  
8.2 Visit 2 (Day -10 to Day -1; IOB subjects only)  
 Inclusion/exclusion criteria (befo re BRV dispensed)  
 Concomitant medications including AEDs  
 Body weight (before BRV dispensed)  
 Vital signs BP, pulse rate, RR, and temperature  
 Pregnancy testing for females of childbearing potential (urine)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 37 of 68  AEs 
 C-SSRS (for subjects ≥6 years of age); version per Section  10.3.3  
 Withdrawal criteria  
 Dispense oral BRV  
8.3 Visit 3 (Day 1) through Visit 12 (Day 6)  
 Inclusion/exclusion criteria (Visit 3 only; prior to iv BRV administration)  
 Concomitant medications including AEDs  
 Physical examination (brief) (at Visit 3 prior to the initial dose of BRV and daily thereafter, 
ideally after the morning dose of BRV each da y) 
 Tanner staging at Visit 3 prior to iv BRV administration only.  The Investigator should use 
clinical judgment in deciding which subjects are selected for evaluation of Tanner Stage (ie, 
those subjects who are pubescent).  
 Neurological examination (brief)  (at Visit 3 prior to iv BRV administration and daily 
thereafter, ideally after the morning dose of BRV each day)  
 Body weight (Visit 3 only, prior to iv BRV administration)  
 Body height  
 Vital signs (BP, pulse rate, RR, and temperature) (see Table  5‒2 and Table  5‒3 for timing 
relative to initiation of iv  BRV administration) . The criteria for BP values to be low or high 
PCS values are described in  Table  10-6 . 
 12-lead ECG (see Table  5‒2 and Table  5‒3 for timing relative to initiation of iv BRV 
administration)  
 Pregnancy testing for females of childbearing potential (urine test) (Visit 3 only, prior to iv 
BRV administration)  
 AEs 
 Withdrawal criter ia 
 C-SSRS (for subjects ≥6 years of age); version per Section  10.3.3  (Visit 3 prior to iv BRV 
administration  and, for subjects who receive ≥2 doses of iv BRV and who will enter the 
Down -Titration Period, at their final visit of the iv PK Period [Visit 4 to 12, as applicable])  
 PK sampling (see Table  5‒2 and Table  5‒3 for timing relative to initiation of iv BRV 
administr ation)  
 Collect oral BRV (as needed for IOB subjects who will enter the long -term, open -label 
study)  
 Dispense oral BRV (at final visit of this period and only for subjects who will enter the 
Down -Titration Period)  
 iv BRV administration  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 38 of 68 Subjects who are co ntinuing into the long -term, open -label study after their final dose of iv BRV, 
will re -enter (OLB subjects)/enter (RxB, IOB, and IIB subjects) that study at the completion of 
assessments associated with the final iv dose of iv BRV.  
8.4 TC-1 (Day 2 to Day 9) (all subjects who received iv BRV)  
Telephone Contact -1 (TC -1) should occur 1 to 3 days after the final dose of iv BRV. The 
primary purpose of this contact is to collect information pertaining to possible infusion -related 
AEs. Subjects who report new or wor sened infusion -site related AEs should return for an 
Unscheduled Visit as soon as possible.  
 Concomitant medications including AEDs  
 AEs 
 Withdrawal criteria  
8.5 TC-2 
Telephone Contact -2 is only applicable to subjects who participate in the Down -Titration Period 
for more than 2  weeks; TC -2 should be conducted approximately half way through the 
Down -Titration Period.  
 Concomitant medications including AEDs  
 AEs  
 Withdrawal criteria  
8.6 Visit 13  
This visit is applicable only to subjects who have participated in the Down -Titration Period or to 
subjects who need to withdraw from the study and do not need to have BRV down titrated.  
 Concomitant medications including AEDs  
 Physical examination (brief)  
 Neurological examination (brief)  
 Body height  
 Vital signs (BP, pulse rate , RR, and temperature)  
 12-lead ECG  
 Clinical chemistry, hematology, and endocrinology  
 Urinalysis for subjects for whom urine sample collection is feasible  
 Pregnancy testing for females of childbearing potential (urine test)  
 AEs  
 C-SSRS (for subjects ≥6 years of age); version per Section  10.3.3  
 Collect oral BRV  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 39 of 68 8.7 TC-3 
Telephone Contact -3 is only applicable to subjects who have completed Visit 13 and should be 
conducted 2  weeks after the final dose of BRV.  
 Concomitant medications including AEDs  
 AEs  
8.8 Unscheduled Visit  
If an Unscheduled Visit is needed, then the following assessments will be performed. Additional 
assessments can be  performed at the Investigator’s discretion.  
 Concomitant medications including AEDs.  
 Vital signs (BP, pulse rate, RR, and temperature).  
 AEs.  
 Withdrawal criteria  
 C-SSRS for subjects ≥6 years of age using the version indicated in Section  10.3.3 . If an 
Unscheduled Visit is conducted due to safety reasons, a C -SSRS assessment will be 
performed with the subject during the visit. If the Unscheduled Visit is  conducted for reasons 
other than safety concerns (eg,  replacement of lost medication, repeated collection of a 
laboratory specimen due to collection or analysis issues), a C -SSRS will not be required at 
this visit.  
9 ASSESSMENT OF PHARMA COKINETIC VARIABLES  
The PK sampling will be performed in accordance with the schedule provided in Table  5‒2 
(15-minute [±3 minutes] infusion) and  Table  5‒3 (bolus [up to 2 -minute infusion]). Additional 
PK sampling may be performed at the discretion of the Investigator, especially in the event of a 
relevant treatment -emerg ent AE.  
Blood samples should be collected after completion of the ECG and the vital sign measurements 
and from a region of the body not used for the iv BRV administration. The date, start, and stop 
time of each iv administration and the date and time of ea ch PK sampling must be recorded.  
Per subject, the maximum amount of blood collected for PK analyses and clinical laboratory 
assessments will not exceed a maximum of 3% of the subject’s total blood volume within 
4 weeks.  
Details of plasma sample collection and processing, sample labeling, and shipment will be 
provided in the laboratory manual.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 40 of 68 10 ASSESSMENT OF SAFETY  
10.1 Adverse events  
10.1.1  Definitions  
10.1.1.1  Adverse event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a p harmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of  a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.  
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF/Assent form), including any pretreatment and posttreatment periods 
required by the protocol, must be reported in the CRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or wo rsened after the initial visit.  
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner a s compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period.  
10.1.1.2  Serious adverse event  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. A serious adverse ev ent (SAE) must meet 1 or more of the following criteria:  
 Death  
 Life-threatening  
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)  
 Significant or persistent disability/incapacity  
 Congenital an omaly/birth defect (including that occurring in a fetus)  
 Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed  in the definition of serious  
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section  10.1.1.3 ], allergic bron chospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)  
 Initial inpatient hospitalization or prolongation of hospitaliza tion 
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 41 of 68 admission to the hospital would also qualify for the initial inpatient  hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening a dverse experience, important medical event].  
Hospitalizations for reasons not associated with the occurrence of an AE [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteri stic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)  
10.1.1.2.1  Anticipated serious adverse events  
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure.  
This list does not change the Inves tigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section  10.1.2.3 . 
Table  10‒1: Anticipated serious adverse events for the pediatric epilepsy 
population  
MedDRA SOC  MedDRA PT  
Congenital, familial and genetic disorders  Teratogenicity  
General disorders and administrative site conditions  Sudden unexpected death in epilepsy  
Nervous system disorders  Convulsiona 
Status epilepticus  
Pregnancy, puerperium and perinatal disorders  Abortion spontaneous  
Psychiatric disorders  Psychotic behavior  
Abnormal behavior  
Anxiety  
Sleep disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SOC=system organ class  
a Convulsion if consistent with the seizure type known for the subject.  
10.1.1.3  Adverse events of special interest  
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. For this study, the AEs o f special interest include:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 42 of 68  Autoimmune nephritis  
 Nephritis  
 Nephritis allergic  
 Tubulointerstitial nephritis  
 Tubulointerstitial nephritis and uveitis syndrome  
 Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow -up 
informat ion should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.  
10.1.2  Procedures for reporting and recording adverse events  
The subject and/or caregiver (including parent/legal guardian) will be given the opportunity to 
report AEs spontaneously. A general prompt will also be given at each study visit to detect AEs. 
For example:  
“Did you notice anything unusual about your health (since your last visit)?”  
In addition, the Investigator should review any self -assessment procedures (eg,  diary cards) 
employed in the study at each visit.  
The AEs should be recorded in the CRF at only the first visit at which they are reported and 
subsequently only if there is a change.  
10.1.2.1  Description of adverse events  
When recording a n AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The CRF and 
source documents should be consistent. Any discrepancies between the subject’s and/or 
caregivers own words on his/her own records (eg,  diary card) and the corresponding medical 
terminology should be clarified in the source documentation.  
Details for completion of the AE CRF (including judgment of relationship to IMP) are described 
in the CRF Completion Guidelines.  
10.1.2.2  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
 The outcome date of the first AE that is not related to the natural course of the disease bein g 
the same as the start date of the repeated AE, and the outcome of “worsening”  
 The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one  
10.1.2.3  Additional procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 43 of 68 section at the front of the pro tocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.  
An Investigator SAE Report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English.  
It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing th e safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.  
Additional information (eg,  autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All do cuments in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report form.  
The Investigator is specifically requested to collect and repor t to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the I nvestigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.  
Upon receipt of the SAE Report form, UCB will perf orm an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the Investigator’s 
Brochure for BRV.  
10.1.3  Follow up of adverse events  
An AE should be followed until it has resolved, has a stable sequelae, the Inv estigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events is provided in Section  10.2.1.4 . 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achie ved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 30  days 
after the subject has discontinued his/her IMP.  
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.  
If new or worsened infusion -site related AEs are reported during TC -1, the subject should return 
for an Unscheduled Visit as soon as possible for further assessment.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 44 of 68 10.1.4  Pregnancy  
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s  PS department by providing the completed 
Pregnancy Report and Outcome form (for contact details see SAE reporting information at the 
beginning of this protocol). The subject should be withdrawn from the study as soon as 
pregnancy is known (by positive pre gnancy test), and the following should be completed:  
 The subject should immediately stop the intake of BRV or be down -titrated as instructed by 
the Investigator.  
 For subjects who have BRV down -titrated:  
 Return for Visit 13.  
 TC-3 should be scheduled 2 weeks  after the subject has discontinued BRV.  
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.  
The pregnancy will be documented on the Pregnancy Report and Outcome form pro vided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every r easonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to  follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collect ion for 
the pregnancy, eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner  Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/contract research organization (CRO) contr act monitor for the 
study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see SAE reporting information at the beginning of this 
protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS department is also the primary 
contact for any questions related to the data collection for the partner pregnancy, eventual birth, 
and follow up.  
A pregnancy becomes a SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any c ongenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 45 of 68 10.1.5  Suspected transmission of an infectious agent via a medicinal 
product  
A suspected transmission of infectious agent is defined as an y infection that is temporally related 
to the administration of the medicinal product with no other likely cause. The medical monitor 
should be contacted immediately. No further medicinal product from that specific batch should 
be administered. Infections should be treated according to normal clinical practice.  
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE mo dule of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
10.1.6  Overdose of investigationa l medicinal product  
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the CRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events a re only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg,  suicide attempt).  
10.1.7  Safety signal detection  
Selected data from this study will be reviewed periodically  to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
The Study Physician or medically qualifi ed designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.  
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified pers onnel at UCB may identify additional safety measures (eg,  AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.  
For further details please refer to Section 12.7.  
10.2 Laboratory measurements  
Laboratory assessments for safety (including hematology, chemistry, and endocrinology for all 
subjects, and urinalysis for subjects for whom sample c ollection is feasible) will be conducted 
using standard methods at a central laboratory. The central laboratory will provide the 
Investigator with dedicated, standardized sampling supplies (labels, needles, tubes) and a 
study -specific laboratory manual, wh ich will explain how to use the supplies and how to ship the 
samples to the central laboratory.  
Pregnancy tests (urine) for female subjects of childbearing potential will be performed locally.  
Table  10‒2 provides a list of laboratory parameters that will be assessed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 46 of 68 Table  10‒2: Laboratory parameters  
Hematology  Chemistry  Urinalysisa Endocrinology Pregnancyb 
WBC  Glucose  Glucose  FSH β-hCG (urine)  
RBC  Sodium  Ketones  LH  
Hemoglobin  Potassium  Occult blood  TSH   
Hematocrit  Calcium  Protein  T3  
Platelet count  Chloride  Nitrites  T4  
Lymphocytes (number, %)  Bicarbonate  Leukocytes    
Monocytes (number, %)  Phosphorus 
(inorganic)  Microscopic 
examinationc  
Neutrophils (number, %)  Total protein     
Eosinophils (number, %)  Albumin     
Basophils (number, %)  Total bilirubin     
MCH  ALP     
MCHC  AST     
MCV  ALT     
 GGT     
 Uric acid     
 Urea     
 Creatinine     
 Triglycerides     
 Cholesterol     
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; β -hCG=beta -human 
chorionic gonadotropin; FSH=follicle -stimulating hormone; GGT=gamma -glutamyltransferase; LH=luteinizing 
hormone; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV= 
mean corpuscular volume; RBC=red blood cell; T3=triiodothyronine; T 4=thyroxine; TSH=thyroid -stimulating 
hormone; WBC=white bl ood cell  
a Urinalysis will be performed in subjects for whom urine sample collection is feasible.  
b For female subjects of childbearing potential only.  
c Includes bacteria, cells, casts, and crystals for all samples.  
For blood samplings, methods to minimize pain are recommended (eg, topical anesthetic or 
microsamplings may be used). Per subject, the maximum amount of blood collected for clinical 
laboratory assessments and PK analyses will not exceed a maximum of 3% of the subject’s total 
blood volume  within 4  weeks.  
10.2.1  Evaluation of PDILI  
The PDILI IMP discontinuation criteria for this study are provided in Section  6.3.1 , with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and Sponsor within 24 hours of  learning 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 47 of 68 of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  10.1.1.3 ), and, if applicable, also reported as an 
SAE (see  Section  10.1.2.3  ).  
Evaluation of PDILI consists of the diagnostic testing and co ntinued monitoring included in 
Table  10‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hep atologist (if applicable; discussed in Section  10.2.1.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assess ment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormal ity is confirmed (details in 
Section  10.2.1.4 ).  
The results of all monitoring, including laboratory testing and other testing, should be made 
availa ble to the study site and Sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests  are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable CRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
Rechall enge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
The table below summarizes the approach to investigate PDILI.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaraceta m EP0065  
   
Confidential  Page 48 of 68  
Table  10‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consult.c 
Medical Monitor 
must be notified 
within 24  hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section  10.2.1.3 ); 
recommended to 
occur at the site 
with HCP.  Monitoring of liver chemistry 
values at least twice per week  
until values normalize, stabilize, 
or return to within baseline 
values.d 
 ≥3xULN  NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.  
≥5xULN 
(and ≥2x 
baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  
Hepatology consult 
required  if ALT/AST 
≥8x ULN.  Immediate, 
permanent IMP 
discontinuation.  Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48  hours 
at the site with 
HCP (see 
Section  10.2.1.3 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaraceta m EP0065  
   
Confidential  Page 49 of 68 Table  10‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  10.2.1.2 ). 
IMP discontinuation 
required if any of 
the following occur:  
 Subject cannot 
comply  with 
monitoring 
schedule.  
 Liver chemistry 
values continue to 
increase  
 Liver chemistry 
values remain 
≥3xULN (and 
≥2x baseline) 
after 2 weeks of 
monitoring 
without 
stabilization or 
evidence of 
resolution.  Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
Investigator).  Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.d 
Immediate IMP discontinuation 
required if :  
 Liver chemistry values 
continue to increase  
 Liver chemistry values 
remain ≥3xULN (and ≥2x 
baseline) afte r 2 weeks of 
monitoring without 
stabilization or evidence of 
resolution  
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline values. d 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaraceta m EP0065  
   
Confidential  Page 50 of 68 Table  10‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare 
practitioner; IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiting, and right u pper quadrant pain or tenderness; hypersensitivity symptoms include 
eosinophilia (>5%), rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed wit h the Medical Monitor.  
c Details provided in Section  10.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabi lization is at the 
discretion of the Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed . 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 51 of 68 10.2.1.1  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepato logist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discus sion should be followed by a full 
hepatology assessment (see Section  10.2.1.3 ) and SAE report (if applicable).  
10.2.1.2  Immediate action: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section  6.3.1  and Table  10‒3 for details).  
When IMP is discontinued, all concomitant medications and herba l supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction of medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be h epatotoxic to a suitable alternative.  
10.2.1.3  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility  that they may have been caused by  the IMP are detailed in 
Table  10‒4 (laboratory measurements) and Table  10‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the Sponsor on the 
corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the ce ntral laboratory.  
The following measurements are to be assessed:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 52 of 68 Table  10‒4: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E  IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥2xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy testb 
PK samplec 
CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM; HBsAg=hepatitis B surface antigen; 
IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential 
drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal  
a  Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity  symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
b Determined only for female subjects of childbearing potential.  
c Blood sample for determination of plasma concentrations of BRV.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 53 of 68 The following additional information  is to be collected:  
Table  10‒5: PDILI information to be collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
 History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
 Adverse r eactions to drugs  
 Allergies  
 Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
 Recent travel  
 Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not  be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal  pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use, if applicable  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or  hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
10.2.1.4  Follow -up evaluation  
Potential drug -induced liver injury events will require follow -up monitoring as described in  
Table  10‒4. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determinati on of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
10.3 Other safety measurements  
All safety assessments are to be conducted at the times specified in the Schedules of Study 
Assessments ( Table  5‒1 and Table  10-6). During the iv  PK Period, intensive assessments of 
ECGs and vital signs are to be conducted at the times specified in Table  5‒2 (15-minute 
[±3 minutes] infusion) and Table  5‒3 (bolus [up to 2 -minute infusion]).  
10.3.1  ECG  
Standard 12 -lead ECGs will be performed.  
The Investigator will determine whether the results of the ECG are normal or abnormal and 
assess the clinical significance of any abnormalities.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 54 of 68 The original ECG tracing will be signed or initialed and dated by the  Investigator, and retained 
as part of the source documentation.  
10.3.2  Vital signs  
Vital signs assessments will include BP (systolic and diastolic), pulse rate, RR, and temperature. 
Vital sign assessments will be performed after the subject is at rest for at lea st 3 minutes, when 
feasible. If subjects have an abnormal vital sign value, the measurement will be repeated at the 
Investigator’s discretion.  
Possibly clinically significant (PCS) vital sign values are defined as those PCS values which 
occur at any time during the study. Additional monitoring of BP is necessary if a low PCS BP 
value occurs at 2 hours after the start of an infusion (Section  5.2). An overview of PCS 
abnormality criteria for BP is presented in  Table  10-6.  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 55 of 68 Table  10-6: PCS Abnormality criteria for the measurement of blood pressure  
Parameter  Age range  Abnormality criteria  
Systolic blood 
pressure  
(mmHg)  <6m <60 
>100  
6m - <3y <70 
>120  
3y - <12y  <80 
>140  
12y - <17y  <90 
>160  
≥17y  ≤ 90 and a decrease from Baseline of ≥20  
≥ 180 and an increase from Baseline of ≥20  
Diastolic blood 
pressure  
(mmHg)  <6m <40 
>65 
6m - <3y <45 
>75 
3y - <12y  <50 
>80 
12y - <17y  <50 
>105  
≥17y  <50 and a decrease from Baseline of ≥15  
>105 and an increase from Baseline of ≥ 15  
m=month,  PCS=possibly clinically significant;  y=year. A month is defined as 30 days; a year is defined as 365.25 
days.  
10.3.3  Assessment of suicidality  
Suicidal ideation and behavior be assessed by trained study personnel using the C -SSRS for 
subjects ≥6  years of age. This scale will be used for screening as well as to assess suicidal 
ideation and behavior that may occur during the study. The C -SSRS will be completed according 
to the t abular schedule of study assessments ( Section  5.2). 
The Investigator’s decision about subject continuation in the study or subject withdrawal from 
the study if the subject has a positive response to the C -SSRS Question 4, should be based on the 
benefit/risk balance for continuation or discontinuation of study treatment in view of the 
individual subject circumstances, condition, attained efficacy, causa lity, alternative risk 
management options, etc. Details of the case must be documented by the Investigator (Principal 
Investigator or other medically qualified staff conducting the C -SSRS) and provided to UCB via 
the SAE reporting process.  
All subjects wh o are ≥6  years of age will complete the following version of the C -SSRS as 
indicated:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 56 of 68  OLB subjects:  
 “Since Last Visit” version at all visits  
 RxB, IOB, and IIB subjects:  
 “Baseline/Screening” version at Visit  1  
 “Since Last Visit” version at subsequent visits  
 Subjects who become 6 years of age during EP0065:  
 "Already Enrolled" version at the first visit at which the subject is 6 years of age  
 “Since Last Visit” version at subsequent visits  
The C -SSRS is not validated for subjects <6 years of age and will  not be used for this population. 
Subjects should be monitored for any changes in mood, ideas, or behavior for warning signs of 
depression. The Investigator should be aware of common warning signs that might be a signal 
for risk of depression. For common s igns and symptoms of depression in children younger than 
6 years old, reference should be made to the current version of the Diagnostic and Statistical 
Manual of Mental Disorders. Parents and caregivers should also be advised accordingly and 
effort should be made at clinic visits to specifically assess potential depression.  
11 STUDY MANAGEMENT AND  ADMINISTRATION  
11.1 Adherence to protocol  
The Investigator should not deviate from the protocol. However, the Investigator should take any 
measure necessary in deviation  from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority,  IRB/IEC, or 
Sponsor.  
After implementation of such measure, the Investigator must notify the Clinical Project Manager 
of the Sponsor within 24 hours and follow any local regulatory requirements.  
11.2 Monitoring  
Monitoring of the study will be delegated by UCB to a CRO. T he CRO will monitor the study to 
meet the Sponsor’s monitoring SOPs, ICH -GCP guideline, and applicable regulatory 
requirements, and to ensure that study initiation, conduct, and closure are adequate.  
The Investigator and his/her staff are expected to coop erate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study -related m onitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Investigator will allow UCB (or designee) to periodically review all CRFs and 
corresponding source documents (eg,  hospital and laboratory records for each study participant). 
Monitoring v isits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of CRFs, ensure that all protocol 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 57 of 68 requirements, applicable authorities regulations, and Investigator’s obligations are bei ng 
fulfilled, and resolve any inconsistencies in the study records.  
11.2.1  Definition of source data  
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (i nk, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self -stick notes). Printouts of CRF screens are not considered acceptable 
source documents.  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.  
Original laboratory results and ECGs are considered as source documents and should be placed 
and stored with the subject’s study information.  
Source do cuments that are computer generated and stored electronically must be printed for 
review by the monitor (eg,  ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documen ts. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records must be saved and stored as instructed by UCB (o r designee).  
11.2.2  Source data verification  
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg,  subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the CRF should be supported by source 
documents, unless otherwise specified in Section 11.2.1 . 
11.3 Data handling  
11.3.1  Case Report form completion  
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in the 
electronic CRFs and in all required reports.  
Any change or correction to the CRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.  
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
CRF.  
Detailed instructions will be provided in the CRF Completion Guidelines.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 58 of 68 11.3.2  Database entry and reconciliation  
Case Report forms/external electronic data will be  entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. The data are entered into the electronic CRFs once and are subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loa ded. 
Regular backups of the electronic data will be performed.  
11.3.3  Subject Screening and Enrollment log/Subject Identification Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data shou ld identify the study and document the dates of the subject’s 
participation.  
11.4 Termination of the study  
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time f or reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.  
If the study is prematurely terminated or suspended, UCB (or its r epresentative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should al so be informed and provided with reason(s) for the 
termination or suspension by the Sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IM P and other material in accordance with UCB procedures for the study.  
11.5 Archiving and data retention  
The Investigator will maintain adequate records for the study, including CRFs, medical records, 
laboratory results, Informed Consent documents, drug dispens ing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing applica tion in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a lon ger period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section  4.9.5]). The Investigator will contact 
UCB for authorization prior to the destruction of any study records or in the ev ent of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 59 of 68 relocate or move the study -related files to a location other than that specified in the Sponsor’s 
study master file.  
11.6 Audit and inspection  
The Investigator will permit study -related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.  
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects  enrolled have been protected, that enrolled subjects (ie,  signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the plan ned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.  
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory a uthority is announced, the Investigator will immediately 
inform UCB (or designee).  
11.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the Sp onsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.  
12 STATISTICS  
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan.  
12.1 Definition of analysis sets  
The Safety Set iv (SS -iv) will include subjects who received at least 1 dose of iv BRV. The SS -iv 
will be the primary analysis set for the analysis of safety data.  
The Safety Set (SS) will include subj ects who received at least 1 dose of BRV (oral or iv). 
Selected safety summaries will be presented for the SS.  
The PK Per -protocol Set (PK -PPS) will include all subjects in the SS having provided at least 
1 measurable postdose plasma sample (with recorded sampling time) during the iv  PK Period 
with documented iv BRV intake times.  
12.2 General statistical considerations  
All computations for the non -PK analyses will be performed using SAS® version 9.3 or later 
(SAS Institute, NC, USA).  
Selected disposition, exposure, demographic, and baseline summaries will be presented by 
cohort and infusion duration (15 -minute [±3 minutes] infusion and bolus [up to 2 -minute 
infusion]), cohorts overall, and across all subjects. Descriptive statistics will be displayed to 
provide an overview of the Baseline characteristics, PK, safety, and tolerability results. For 
categorical variables, these will consist of the number and percentage of subjects in each 
category. The denominator and percentage will be based on the number of s ubjects appropriate 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 60 of 68 for the purpose of analysis. For continuous variables, display of descriptive statistics will 
generally include n (number of subjects), mean, standard deviation (SD), median, minimum, and 
maximum.  
12.3 Planned PK analyses  
Descriptive statist ics for BRV plasma concentrations, including but not limited to geometric 
mean and coefficient of variation percentages, will be computed for pre -bolus/infusion and at the 
post-bolus/infusion time points on each for iv BRV administration during the iv  PK P eriod.  
12.4 Planned safety analyses  
Safety data will be reported in epochs that include the pre -bolus/infusion period(s), the 
bolus/infusion period(s), the period(s) immediately post -bolus/infusion, and period(s) between 
each subsequent bolus/infusion(s). These  data will include vital signs, ECGs, and AE reporting.  
12.4.1  Analysis of safety variables  
Descriptive statistics for the safety variables will be presented by cohort and infusion duration, 
cohorts overall, and all subjects overall. Additional summaries will in clude a summary of the 
OLB, RXB, IOB, and IIB groups by cohort and infusion duration.  
12.4.1.1  Primary safety variables  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®). Adverse events will be summarized by MedDRA System  Organ Class and 
Preferred Term.  
The primary safety variables will be summarized for the iv PK Period for the SS -iv. Summaries 
of adverse events will also be presented by study period for the SS and epochs relative to 
bolus/infusion for the SS -iv. 
12.4.1.2  Other sa fety variables  
Inferential statistical tests are not planned for the other safety variables. In general, for 
continuous safety variables including ECG measurements including corrected QT interval , and 
vital sign measurements, the descriptive analyses (n, m ean, SD, median, minimum, maximum) 
for the actual measurement and its change from baseline (defined as most recent pre -iv BRV 
measurement) will be presented by epochs relative to bolus/infusion. When analyzing categorical 
data, the number and percentage of  subjects in each category will be presented. In addition, shift 
tables may be used to evaluate the number and percentage of subjects having a different post -iv 
BRV status when compared with their pre -iv BRV status for each bolus/infusion. Changes in 
vital signs and ECG parameters will be presented graphically for epochs relative to 
bolus/infusion.  
12.5 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on the primary sa fety outcomes for an individual subject. The criteria for 
identifying important protocol deviations will be defined within the appropriate protocol -specific 
document. Important protocol deviations will be reviewed as part of the ongoing data cleaning 
proce ss and data evaluation. All important deviations will be identified and documented prior to 
database lock to confirm exclusion from analysis sets.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 61 of 68 12.6 Handling of dropouts or missing data  
No specific procedure is foreseen for handling dropouts or missing data.  
12.7 Planned interim analysis and data monitoring  
No formal interim analysis is planned for this study.  
For the first cohort, after the first half of the subjects receive the 15 -minute infusion(s), the DMC 
will meet to review safety (as indicated in the DMC c harter) and, as available, PK data. For 
subsequent cohorts, the DMC will review data for bolus infusions of the previous cohort and the 
15-minute infusions of the current cohort. The DMC will meet no less than approximately every 
6 months commensurate with  enrollment.  
12.8 Determination of sample size  
The primary objective of the study is to evaluate the PK, safety, and tolerability of BRV given 
intravenously. The plan for approximately 50 enrolled subjects (4  cohorts of 
approximately12  subjects each) to receive  iv BRV was deemed clinically appropriate for the 
evaluation of the PK, safety, and tolerability of iv BRV administration in subjects ≥1 month to 
<16 years of age with epilepsy. No formal sample size calculation has been performed.  
13 ETHICS AND REGULATOR Y RE QUIREMENTS  
13.1 Informed consent  
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study an d its alternatives with 
the Investigator.  
Prior to participation in the study, the written Informed Consent form should be signed and 
personally dated by the subject, or his/her legal representative, and by the person who conducted 
the informed consent discussion (Investigator or designee). The subject or his/her legal 
representative must receive a copy of the signed and dated Informed Consent form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for 
study -related monitoring, auditing, IRB/IEC review, and regulatory inspection. In addition, a 
Consent form or a specific Assent form, where required, will be signed and dated by minors. 
Any subject who becomes 16 years of age during EP0065 must sign and da te the Informed 
Consent form according to local regulations.  
If the ICF/Assent form is amended during the study, the Investigator (or the Sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended I nformed Consent form by the IRB/IEC and use of the amended form.  
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 62 of 68 The subject or legal representative may  withdraw consent for the subject to participate in the 
study at any time. A subject is considered as enrolled in the study when the subject or legal 
representative has signed the ICF form/Assent form. A CRF must not be started, nor may any 
study specific procedure be performed for a given subject, without having obtained the written 
consent of the subject or legal guardian for the subject to participate in the study.  
13.2 Subject identification cards  
Upon signing the ICF and Assent form (as applicable), the sub ject or legal representative will be 
provided with a subject identification card in the language of the subject. The Investigator will 
fill in the subject identifying information and medical emergency contact information. The 
Investigator will instruct the  subject to keep the card with him/her at all times.  
13.3 Institutional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical pr inciples that have their origin in the Declaration 
of Helsinki.  
The Investigator/UCB (or designee) will ensure that an appropriately constituted IRB/IEC that 
complies with the requirements of the current ICH -GCP version or applicable country -specific 
regul ations will be responsible for the initial and continuing review and approval of the clinical 
study. Prior to initiation of the study, the Investigator/UCB (or designee) will forward copies of 
the protocol, ICF/Assent form, Investigator’s Brochure, Investi gator’s curriculum vitae (if 
applicable), advertisement (if applicable), and all other subject -related documents to be used for 
the study to the IRB/IEC for its review and approval.  
Before initiating a study, the Investigator will have written and dated fu ll approval from the 
responsible IRB/IEC for the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate  immediate hazards to subjects.  
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved pr otocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will a lso be informed by the Investigator or the Sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 63 of 68 Investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC 
notificat ion. 
13.4 Subject privacy  
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.  
The Investigator agrees t hat representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, bu t not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).  
13.5 Protocol amendments  
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.  
Significant changes to the protocol will only be made as an amendm ent to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.  
14 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insuran ce, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 64 of 68 15 REFERENCES  
Banerjee PN, Hauser WA. Epilepsy: A comprehensive textbook. In: Engel J, Pedley TA, editors. 
Incidence and prevalence. Philadelphia: Wolters Kluw er/Lippincott Williams & Wilkins; 2008. 
p. 45 -56. 
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Hadjiloizou SM, Bourgeois BFD. Antiepileptic drug treatment in children. Expert Rev 
Neurother. 2007;7:179 -93. 
Hauser WA, Annegers  JF, Kurlank LT. Incidence of epilepsy and unprovoked seizures in 
Rochester, Minnesota: 1935 -1984. Epilepsia. 1993;34:453 -68. 
Theodore WH, Spencer SS, Wiebe, S, Langfitt JT, Ali A, Shafer PO. Epilepsy in North America: 
a report prepared under the auspices of the global campaign against epilepsy, the International 
Bureau for Epilepsy, the International League Against Epilepsy, and the World Health 
Organization. Epilepsia. 2006;47:1800 -22. 
Wirrell, EC, Grossardt BR, Wong -Kisiel LC, Nickels KC. Incidence and c lassification of 
new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 
1980 to 2004: a population -based study. Epilepsy Res. 2011;95;110 -8. 
Zarrelli MM, Beghi E, Rocca WA, Hauser WA. Incidence of epileptic syndromes in Roc hester, 
Minnesota: 1980 -1984. Epilepsia. 1999;40:1708 -14. 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 65 of 68 16 APPENDIX  
16.1 Protocol Amendment 1  
Rationale  
This nonsubstantial amendment is based on DMC recommendation, as a precaution additional 
safety monitoring has been added to the protocol. This precaution w as not based on any related 
AE or reported  symptoms. Additional  vital sign  measurements , specifically blood pressure, and 
criteria for further iv BRV dose allocation were added to further investigate blood pressure 
changes and ensure safety. Additionally, height measurements have been collected at various 
visits since the onset of the study, while these were inadvertently  absent from the list of 
assessments. The protocol has therefore been aligned .  
Specific changes  
Section # and name Descript ion of change  Brief rationale  
Study contact information  Updated Sponsor Study 
Physician, Clinical Project 
Manager, and Clinical Trial 
Biostatistician  Recent changes in study 
contacts  
Section 5. 2 Schedule of study 
assessments  Added definition of PCS  
 
Added cross reference to BP 
PCS values Table 10 -6 
Added text regarding 
additional safety monitoring  
and criteria for further iv and 
BRV dose allocation  Absent from previous version  
 
To clearly define BP PCS 
values  
To further investigate BP and 
ensure safet y 
Table 5 -1 Schedule of Study 
Assessments (Screening 
Period through end of iv PK 
Period)  Added  body  height  
assessment  Added this text that was 
inadvertently omitted during 
protocol development  
Table 5 -2 Schedule for iv PK 
Period ECGs, vital signs, and 
PK sampling (15 -min BRV 
infusion)  Added BP assessment along 
at 2hrs post infusion start and 
accompanying footnote  
Added description of when 
additional BP monitoring is 
required  To further investigate BP and 
ensure safety  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 66 of 68 Section # and name Descript ion of change  Brief rationale  
Table 5 -3 Schedule for iv PK 
Period ECGs, vital signs, and 
PK sampling (bolus [up to 
2-min BRV infusion])  Added BP assessment along 
at 2hrs post infusion start and 
accompanying footnote  
Added description of when 
additional BP monitoring is 
required  To further investigate BP and 
ensure safety  
Table 5 -4 Schedule of study 
assessments for Down -
Titration and Safety (BRV -
free) Periods (subjects not 
continuing into the Long -
Term, Open -Label Study)  Added body height 
assessment  Added this text that was 
inadvertently omitted during 
Protocol developmen t 
Section 8.1 Visit 1 (Day -10 
to Day -1 for OLB, RxB, and 
IIB subjects; Day -20 to Day -
11 for IOB subjects)  Added body height 
assessment  Added this text that was 
inadvertently omitted during 
Protocol development  
Section 8.3 Visit 3 (Day 1) 
through Visit 12 (Day 6)  Added body height 
assessment  
 
 
Added a cross reference to 
BP PCS values Table 10 -6 Added this text that was 
inadvertently omitted during 
Protocol development  
 
To clearly define BP PCS 
values  
Section 8.6 Visit 13  Added body height 
assessme nt Added this text that was 
inadvertently omitted during 
Protocol development  
Section 10.3.2 Vital signs  Added text regarding 
additional safety monitoring  
 
Added Table 10 -6 PCS 
abnormality criteria for the 
measurement of BP  To further investigate BP and 
ensure safety  
 
To describe the criteria for 
systolic and diastolic BP to 
be low or high PCS  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 67 of 68 17 DECLARATION AND SIGN ATURE OF INVESTIGATO R 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.  
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.  
I have received and read all study -related informa tion provided to me.  
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.  
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.  
Investigator:  
 
   
Printed name    Date/Signature  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   19 Jun 2019  
Clinical Study Protocol  Brivaracetam  EP0065  
   
Confidential  Page 68 of 68 18 SPONSOR DECLARATION  
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: ep0065-protocol-amendment-1
Version: 1 . 0
Document Number: CLIN-000135150
Title: EP0065 Protocol-Phase 2-Open-label
Approved Date: 20 Jun 2019
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 19-Jun-2019 11:57:23 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Qualified Person
Date of Signature: 19-Jun-2019 12:12:50 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 20-Jun-2019 10:09:09 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 